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CHAPTER 1.  Introduction 
1.0 Source Material 
Unless otherwise stated, the source material for sections 1.2-1.4 is a 
combination of five sources: four reviews[31,156,173,174] and one textbook[75].  
The reviews are especially well-written and offer timely snapshots of the pediatric 
AML field and are highly recommended. 
1.1  Purpose 
Acute myeloid leukemia (AML) is a potentially devastating disease that 
can affect people of all ages.  While there are certain patient groups that typically 
have favorable outcomes, AML carries a relatively poor prognosis for most age 
groups when compared to other acute lymphoblastic leukemia (ALL).  
Furthermore, the treatment for AML typically consists of rigorous 
chemotherapeutic regimens and bone marrow/stem cell transplant, both of which 
are associated with severe acute and chronic toxicity and the potential for 
treatment-related mortality.  In order to improve both survival and survivorship 
after the diagnosis of AML, the development of better treatment options is of 
paramount importance.   
1.2 Hematopoiesis 
 Like other hematologic malignancies, AML is the result of unchecked 
proliferation of immature cells from a hematopoietic lineage.   Hematopoiesis is 
the lifelong process by which the cellular components of blood are produced.  In 
general, these components can be classified as either lymphoid (e.g. T- and B-
cells) or myeloid (e.g. red blood cells [RBCs] and neutrophils), and each type of 
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cell plays a specific role within the body.  For the sake of clarity, the traditional 
dichotomous understanding of hematopoiesis will be presented here, although it 
is important to note that this model has come under question in recent years[96]. 
1.2.1 Locations of hematopoiesis 
 As development progresses from embryo to adult, hematopoiesis occurs 
at varying locations throughout the body.  Initially, hematopoiesis begins in the 
yolk sac of the developing embryo, and occurs exclusively at this site until the 
development of the fetal liver.  As the liver develops, it eventually is the home to 
the majority of hematopoiesis, although there is a minor role for the fetal spleen 
for a brief period.  Eventually, as the skeletal system and the marrow 
compartment develop, hematopoiesis begins to occur primarily in red marrow.  
Though there is a minor role for lymphatic organs in hematopoiesis later in life, 
red marrow remains the primary site of hematopoiesis until death. 
1.2.2 Lymphocytic hematopoiesis and the role of major lymphoid lineages 
 Though not the focus of the work presented herein, the lymphocytic 
compartment is responsible for the majority of acquired immunity and cancer 
prevention in humans, and until recently, deficiencies in this compartment were 
largely incompatible with post-natal survival.  Derived from a common 
hematopoietic stem cell (HSC), the lymphoid lineage produces T-cells, B-cells, 
and natural killer (NK) cells.  When a HSC is stimulated by the correct external 
factors, which include extracellular signals from cytokines like notch-ligand and 
certain interleukins, as well as internal factors, like expression of the proper 
transcription factors, it develops into a common lymphoid progenitor.  From this 
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state, the decision is made, again by a combination of internal and external 
factors, to differentiate into one of the terminal lymphoid lineages. 
 1.2.2.1 B-cells  Antibody production, which is required for a rapidly acting 
adaptive immune system, is the major responsibility of the B-cell lineage.  Pre-B 
cells migrate from the marrow to secondary lymphatic organs like the spleen or 
lymph node, where they await further stimulation.  These cells then undergo 
recombinatorial rearrangement of the B-cell receptor, which eventually forms the 
scaffold for the variable region of an antibody.  Upon antigen recognition, these 
pre-B cells become mature B-cells, and can then differentiate into plasma cells 
for antibody production, or memory B-cells which are long-lived cells that help to 
preserve immunity.  Interrogation of B-cell development has led to great 
advances in the understanding of DNA repair and cellular maturation processes, 
however, in depth discussion of these processes is beyond the scope of this 
work.   
Of particular note is the somewhat unique case of plasma cell malignancy.  
Multiple myeloma (MM) is a disease characterized by uncontrolled proliferation of 
non-functional plasma cells.  The natural history of this disease is quite different 
from those of other hematologic malignancies, and unfortunately MM is usually 
fatal.  Though not discussed specifically here, as MM is not diagnosed in 
pediatric patients, good treatment overviews can be found in reviews by Stewart 
et al. and Mehta et al.[130,194]. 
 1.2.2.2 T-cells  Like B-cells, T-cell precursors migrate out of the bone 
marrow to finish differentiation in a secondary location, in this case, the thymus.  
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It is in the stroma of the thymus that the highly regulated process of T-cell 
maturation occurs.  Though there are several subtypes of T-cells, the most 
commonly discussed are those that express either CD4 or CD8.  Helper T-cells, 
or CD4+ cells, represent a variety of cells that act to enhance or reduce the 
amount of immune activation in response to a stimulus.  This compartment is 
necessary for the full function of the acquired immune system, as CD4+ cells are 
required for complete activation of CD8+ cytotoxic T-lymphocytes as well as 
isotype switching in B-cells.  In contrast, CD8+ cells, which at terminal maturation 
become cytotoxic T-lymphocytes, are responsible for the recognition and 
extermination of virally infected and otherwise transformed (including malignant) 
cells.   
 1.2.2.3 Natural Killer Cells  Occupying somewhat of a different role in the 
lymphoid compartment are NK cells.  The activation of and target recognition by 
NK cells is a complicated matter, but the important feature of NK cells is that they 
are able to target cells without prior exposure to an insult.  These cells recognize 
target cells through a combination of down-regulated major histocompatibility 
complex I and antibody coating.  By recognizing these features, which are 
common in virally infected and malignantly transformed cells, NK cells are able to 
help clear potentially dangerous host cells. 
1.2.3 Myeloid hematopoiesis – a general overview 
 The alternative to lymphocyte production is progression down the myeloid 
lineage.  At various stages, the presence of extracellular signaling molecules 
(discussed in this section), stromal interactions, and transcription factor 
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expression (discussed in section1.3.2) all combine to drive progression towards a 
specific lineage.  The first major decision after myeloid commitment is whether or 
not to produce granulocytes.  If the granulocyte decision is made, development 
will progress through the myeloblast stage culminating in either basophil, 
eosinophil, neutrophil, or monocyte production.  The alternative to the 
granulocyte pathway is the erythrocyte/megakaryocyte lineage, which will be 
discussed in detail below in section 1.2.3.1. 
 Just as in lymphoid development, there is an important role for 
extracellular signaling molecules in myeloid hematopoiesis and lineage 
determination.  Important cytokines for myeloid differentiation include, among 
others, interleukins 3, 4, and 5, stem cell factor (SCF), granulocyte-colony 
stimulating factor, and granulocyte/macrophage-colony stimulating factor (G-CSF 
and GM-CSF, respectively).  These cytokines activate a variety of intracellular 
pathways, but many bind receptor tyrosine kinases, with eventual activation of 
the Janus-kinase/signal transducer and activator of transcription (Jak-STAT) and 
mitogen-activated protein kinase (MAPK) pathways.  Though a detailed 
description of these pathways is beyond the scope of this work, these commonly 
activated pathways have pleiotropic effects, and can cause changes in 
intracellular signaling cascades, protein localization, and transcription/protein 
expression. 
SCF serves as the ligand for the c-kit receptor, which is highly expressed 
in most myeloid lineages as well as in many AML cases.  Expression of c-kit, and 
subsequent activation by its ligand, is required for hematopoiesis and survival.  
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Though less commonly thought to be driving mutations in AML, mutations in c-kit 
are in fact driving mutations for a type of tumor known as gastrointestinal stromal 
tumor, or GIST.  The colony-stimulating factors G-CSF and GM-CSF play a role 
in lineage decision, and variations in their levels help drive production of specific 
myeloid cells.   
Another factor important for discussion here, due to its association with 
malignant phenotypes, is the fms-like tyrosine kinase 3 (FLT3) ligand (FL).  The 
FLT3 receptor can be found on many hematopoietic cell types, and its activation 
drives enhanced proliferation and survival.  Interestingly, knockout of FLT3 is not 
lethal, and administration of FL alone has little effect.  However, FL appears to 
substantially enhance the effect of many other cytokines.  Unfortunately, as 
discussed below, aberrant activation of the FLT3 axis has deleterious effects. 
1.2.3.1 Erythropoiesis and Thrombopoiesis  After the common myeloid 
progenitor stage, cells have an opportunity to differentiate towards what is 
referred to as a megakaryocyte-erythroid progenitor (MEP).  At this point, though 
there is some disagreement as to how, a cell has to determine which lineage to 
pursue.  In order to differentiate down the erythroid lineage, the master regulator 
of erythropoiesis, GATA1, must be expressed.  The product of the GATA1 gene 
on the X chromosome, GATA1, is an essential transcription factor for the 
development of the erythroid compartment.  The presence of GATA1 is an 
absolute requirement for maturation of erythroid precursors and definitive (late-
stage) erythropoiesis, and mice that lack functional GATA1 protein die in utero of 
severe anemia.  GATA1 binds and activates many genes important for 
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erythropoiesis, including the erythropoiesis-stimulating growth factor 
erythropoietin (EPO).  It does this, at least in part, in collaboration with another 
transcription factor named “friend of GATA1” (FOG1).  FOG1 interacts with the 
N-terminus of GATA1 and enhances the transcription of genes.  This interaction 
is required for definitive erythropoiesis, but is not essential early in the erythroid 
differentiation process. 
Alternatively, the MEP can produce megakaryocytes, which are giant cells 
that function to produce platelets.  Like erythropoiesis, megakaryopoiesis also 
requires fully functional GATA1 and FOG1 to progress to completion.  Uniquely, 
however, is the requirement for thrombopoietin (TPO), which is produced 
constitutively in the liver and kidney.  After binding the TPO receptor, intracellular 
Jak-STAT signaling pathways are activated and serve to drive maturation and 
eventual thrombopoiesis.  Once sufficiently mature, megakaryocytes begin the 
interesting process of endomitosis, in which the cell’s genetic material is 
replicated and the cytoplasm size increases, but only the nucleus divides.  This 
process continues, and megakaryocytes with ploidy as high as 128N have been 
reported.  The motivations for maintaining such large amounts of genetic material 
are slightly unclear, but it is thought that the additional DNA allows for more 
effective transcription and subsequent maintenance of such large cells.  Fully 
mature megakaryocytes’ main function is the production of platelets, the function 
of which will be discussed below. 
1.2.4  Roles of mature myeloid cells 
1.2.4.1 Red Blood Cells.  The most prominent circulating myeloid cell is 
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the erythrocyte, or red blood cell (RBC).  They play the predominant role in the 
transport of oxygen from the lungs to the deep tissues of the body, and are what 
give blood its characteristic red color.  These traits are both due to the presence 
of iron-conjugated heme groups in hemoglobin – a heme containing protein that 
is present in vast quantities in RBCs.  While the absolute number of RBCs is 
important for some disease states, it is the quantity of hemoglobin that is the 
most useful clinically, because it is the most correlated with oxygen carrying 
ability.  In fact, anemia is typically defined by a lack of hemoglobin rather than a 
low RBC count.   
The RBC is unique in many ways among cells in the human body, most 
notably for the lack of nuclei in mature cells.  The absence of a nucleus prevents 
the cell from being able to replenish proteins in response to stress, giving RBCs 
a finite life span, which is typically on the order of 100 days in a healthy adult.  As 
the RBC ages, membrane changes allow the cell to be recognized by 
macrophages in the liver, spleen, and lymph nodes, which phagocytose the cell, 
clearing it from circulation.  This constant destruction requires active 
replenishment, and as a result, RBCs are produced for the duration of a person’s 
life.  Of clinical importance is the detectability of recently produced RBCs in the 
peripheral circulation.  These cells, which still possess varying degrees of 
ribosomal RNA are termed reticulocytes, and can be identified by stains that can 
detect the remaining RNA, such as methylene blue.  As the cell matures further, 
this RNA is eventually degraded, and thus RNA content can be used to judge the 
age of the RBC.  The quantity of circulating reticulocytes is a useful parameter to 
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interrogate because it gives an index of how actively the bone marrow is 
producing new RBCs, i.e., a high reticulocyte count indicates higher rates of 
production.  This has utility during chemotherapy treatment, because it helps an 
oncologist to predict whether a patient’s hemoglobin will trend upward or 
downward. 
Clinically, and most relevant to this work, the most common problem 
associated with RBCs is anemia, typically defined by low hemoglobin.  Low 
hemoglobin reduces the ability to deliver oxygen to peripheral tissues, and can 
be fatal in extreme cases.  Anemia, when sufficiently acute and of substantial 
magnitude, typically presents as decreased energy, and is common in cancer 
patients receiving myelosuppressive chemotherapy.  Fortunately, anemia can 
usually be managed (though not without potential complications) with infusion of 
packed RBCs and appropriate dosing schedules.   
1.2.4.2 Neutrophils  Often considered the first line of defense against 
infection, neutrophils are the most common granulocytes and typically make up 
the majority of circulating leukocytes.  The role of neutrophils is to seek out and 
destroy insults, as well as enhance inflammatory responses.  Primarily directed 
against invading bacteria, neutrophils are able to phagocytose bacteria and 
attempt to kill the microorganism using highly reactive oxygen species in a 
process that has been termed the “respiratory burst”.  The neutrophil also 
releases several other pro-inflammatory cytokines that aid in the recruitment and 
activation of other immune mediators.  The pro-inflammatory nature of these cells 
is offset at least partly by their short life span; neutrophils only live for a few days. 
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Neutropenia, or low levels of neutrophils, can be a medical emergency 
and is commonly seen in patients receiving myelosuppressive chemotherapy.  
When patients’ neutrophil counts are depressed, their susceptibility to infection 
skyrockets, and what are normally benign bacteria can become life-threatening.  
Unfortunately, unlike RBCs, neutrophils cannot be transfused so the best 
defense against profound neutropenia is prevention coupled with supportive care 
(typically prophylaxis against bacterial infection with antibiotics and aggressive, 
usually broad-spectrum antibiotic administration when infection is suspected).  
Prevention has historically been achieved through optimization of dosing 
regimens, careful monitoring of absolute neutrophil counts (ANC), and 
administration of G-CSF (generic: filgrastim) to increase neutrophil production. 
1.2.4.3 Other granulocytes  The remaining myeloid cell types, while 
important in their own right, are mostly relevant to leukemia for the potential of 
their lineages to become malignant.  Monocytes are large circulating 
granulocytes that migrate to tissue and differentiate into various macrophage 
subtypes.  The principle role for these macrophages is phagocytosis of cellular 
debris and invading pathogens.  After phagocytosis, engulfed proteins are broken 
down and presented for antigen recognition by the adaptive immune system.  
Eosinophils are granulocytes that secrete pro-inflammatory markers as well as 
proteins that help defend against certain parasites.  Basophils are the least 
common form of circulating granulocyte, and function to secrete pro-inflammatory 
markers involved in allergic responses.  Lastly, mast-cells are very similar to 
basophils, except they extravasate and take up residence in various tissues 
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throughout the body.  Malignant transformation of these last three lineages is 
rare, but can be associated with poor outcomes and high symptomatic burden 
[111]. 
1.2.4.4 Megakaryocytes and Platelets On the opposite end of the 
spectrum from the small, anuclear RBCs are the megakaryocytes.  These 
massive, multinuclear cells exist to produce platelets, which, like RBCs, lack 
nuclei and serve somewhat as a delivery mechanism for their contents.  Platelets 
are extremely small cellular fragments that bud off of megakaryocytes (the exact 
mechanism by which this occurs is somewhat unclear) and serve to maintain 
hemostasis by providing the cellular components of the clotting cascade.  
Though their lifespan is only on the order of one week, and typical counts are on 
the order of 105/μL, a healthy individual can easily maintain platelet levels with 
each megakaryocyte producing approximately 5,000 to 10,000 platelets over 
their lifespan.  Like other cells of myeloid derivation, platelet levels can be 
jeopardized by myelosuppressive chemotherapy.  Because low platelet counts 
prevent adequate clotting, hemodynamic instability is a major concern for 
thrombocytopenia-inducing antileukemic interventions.  Fortunately, similar to 
RBCs, platelets can be transfused; however their short life span and their high 
cost dictate that this is only done when absolutely necessary. 
1.3 Leukemia 
 Leukemia can be loosely defined as an aberrant hyperproliferation of 
immature blood cells that do not form solid tumor masses (i.e. liquid cancer).  In 
general, leukemia can be either of the myeloid or lymphoid lineages, and 
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classified as being acute or chronic in nature.  Chronic leukemias tend to have 
more mature cells, and are rare in pediatric patients.  Acute leukemias, on the 
other hand, are typically less mature and commonly occur in patients of all ages 
and are potentially rapidly fatal if not readily treated; in fact, acute lymphoblastic 
leukemia (ALL) is the most common childhood malignancy.  Similar to AML, and 
in some cases, on the same disease spectrum, are the myelodysplastic 
syndromes (MDS).  These are a set of diseases that, while not always 
considered malignant, can be deadly, are sometimes treated with chemotherapy 
and often progress to AML.  Though not discussed in this work, a good review of 
MDS can be found in reviews by Stone and Fenaux & Adés[40,196]. This work 
focuses on pediatric AML. 
1.3.1 Epidemiology of Pediatric AML 
 Accounting for approximately 18% of childhood leukemia diagnoses, AML 
is one of the more common childhood cancer diagnoses.  The risk for developing 
AML in the majority of cases is biological rather than environmental, with the only 
established pediatric AML cause being in utero exposure to ionizing radiation.  
Other exposures, e.g. maternal chemical exposure and parental age, have only 
limited evidence supporting their association with AML.  In America, the overall 
incidence of pediatric AML is approximately 7.7 cases per million children.  Race 
appears to play only a very minor role in AML risk among Americans, with Asian 
and Pacific Islanders having the highest incidence (8.4 per million) and African 
Americans having the lowest risk (6.6 per million).  The risk of childhood AML 
peaks early in life at 18 per million in infants less than 1 year of age, reaches an 
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incidence of approximately 4 per million in children aged 5-9.  The factors that 
convey the most risk are genetic.  Down syndrome (DS) is the most common 
genetic risk factor, however, less common diseases, especially those associated 
with DNA repair deficiencies like Fanconi anemia and ataxia telangiectasia are 
also associated with an elevated risk to develop pediatric AML.  For a more 
thorough overview of the epidemiology surrounding pediatric AML, please see 
the 2013 review by Puumala[157]. 
1.3.2 Biology of Pediatric AML 
 Originally divided into only a few morphological subtypes, advancements 
in molecular medicine have allowed for the reclassification of AML subtypes 
based on the vast array of different morphological, cytogenetic, and genetic 
variations that can be seen.  One of the first major attempts at classification 
came with the development of the French-American-British (FAB) system in 
1976[10].  The FAB system divided AML into 8 different subtypes, M0-M7, which 
correspond to: acute myeloblastic leukemia, minimally differentiated (M0); acute 
myeloblastic leukemia, without maturation (M1); acute myeloblastic leukemia, 
with granulocytic maturation (M2); acute promyelocytic leukemia (APL) (M3); 
acute myelomonocytic leukemia (M4); acute monoblastic/monocytic leukemia 
(M5a/b); acute erythrocytic leukemia (M6); acute megakaryocytic leukemia (M7, 
AMKL).  Though less commonly used for prognostic indications, the FAB 
classification is well-entrenched in modern hematology and is commonly referred 
to in conjunction with the more modern World Health Organization (WHO) 
classification. 
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 The WHO classification for myeloid neoplasms represents an attempt at 
offering a comprehensive classification scheme based on all available clinical, 
morphologic, cytochemical, immunophenotypic, and genetic data.  While 
substantially more complicated than the older FAB systems, the WHO 
classification (now in its 4th edition) allows for a much finer differentiation and 
therefore is capable of offering more accurate prognostic correlations.  The major 
categories are: AML with recurrent genetic abnormalities; therapy related myeloid 
neoplasms; myeloid proliferations related to Down syndrome; and AML not 
otherwise specified, which then falls back on the older FAB system.  A full 
discussion of this classification system is beyond the scope of this work, but a 
2009 review of the changes performed by Vardiman et al.[210] covers many of 
the important changes and is a good starting point for those with further interest.  
Instead, some of the major subtypes with prognostic significance, and 
significance to the work presented herein will be covered in more detail. 
1.3.2.1 Core Binding Factor Leukemia  Core binding factor (CBF) AML 
describes a subset of leukemias that possess genetic alterations in one of the 
two proteins that make up the family of protein complexes known as CBFs.  A 
heterodimer, CBF is a transcription factor that consists of DNA-binding α- and 
non-DNA binding β-subunits.  In AML, the α-subunit is encoded by the RUNX1 
gene on chromosome 21, also known as AML1.  The β-subunit is encoded by the 
CBFβ gene on chromosome 16.  The CBF transcription factor plays an important 
role in normal hematopoiesis, and small perturbations of its expression or 
function can have deleterious consequences, AML being just one (for a more 
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comprehensive overview of CBF functions in hematologic physiology and 
disease, see the 2002 review by Speck and Gilliland[190]).  Together, two 
common cytogenetic abnormalities make up the largest group of CBF leukemias: 
t(8;21)(q22;q22) and inv(16)(p13.1q22), representing approximately 15% and 6% 
of pediatric AML cases, respectively.  Despite these translocations both targeting 
the CBF complex, each subtype has its own WHO classification, the prognostic 
implications for which will be discussed below.   
1.3.2.2 APL with PML-RARα fusion gene  Somewhat unique among the 
early FAB classifications was the M3 subgroup, which represents APL.  As the 
name suggests, most of the leukemic cells are abnormal promyelocytes, and in 
most cases, many of the cells will have Auer rods.  Though not pathognomonic 
for APL, the presence of Auer rods, which are fused and typically elongated 
granules, is easily detected by standard microscopic analyses.  This is useful, 
because it allows for a rapid narrowing of diagnoses which is important as newly 
presented APL is a medical emergency.  More so than other AML subtypes, APL 
is associated with an extremely high rate of fatal hemorrhage. 
  Interestingly, almost every case (approximately 95%) of APL has a 
characteristic t(15;17)(q22;q21) translocation which results in the fusion of the 
PML and RARA genes.  The PML gene product PML is important for nuclear 
body formation and plays a role in transcriptional regulation and tumor 
suppression.  The RARA gene product, retinoic acid receptor alpha (RARα) is a 
nuclear receptor that normally plays a role in a host of differentiation processes.  
When these two genes fuse, the resultant protein prevents both of the 
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physiologic functions.  Instead, the PML-RARα fusion protein binds to DNA and 
acts in a dominant negative fashion to repress gene expression as well as 
nuclear body formation.  This prevents further differentiation of the APL cell, and 
while not sufficient, is considered necessary for the development of APL.  
Though APL used to be almost universally fatal, this unique biology allows for the 
use of targeted therapies (discussed below) that make APL one of AML subtypes 
with a more favorable prognosis.  In approximately 5% of cases, the RARA gene 
is fused with another partner protein, resulting in variable changes to 
chemotherapy sensitivity and prognosis. For more information, see the 2005 
review by Zhou et al.[233]. 
1.3.2.3 Therapy-related myeloid neoplasms  In a departure from most 
WHO classifications, myeloid neoplasms (both AML and MDS) that are believed 
to be sequelae of previous therapy are grouped together into the same category 
(tAML).  Many types of cancer treatments act by inducing structural damage to 
DNA (these mechanisms are discussed in depth in Chapter 3).  In the process of 
repairing this damage, it is possible that new genetic abnormalities may arise, 
some of which may aid in the progression to AML.  As this process takes time, in 
many cases years, tAML is less common in children, mostly because by the time 
tAML develops the patient has reached adulthood.  However, tAML is a potential 
consequence of many types of therapy, especially topoisomerase II poisons and 
radiotherapy, both of which are commonly used to treat childhood malignancy. 
Though tAML is not defined by any specific set of genetic abnormalities, 
there are trends that arise.  The use of certain chemotherapy drugs, especially 
17 
 
 
anthracyclines and etoposide, are highly correlated with the development of 
tAML with chromosomal abnormalities involving 11q23.  At this locus is the MLL 
gene (officially referred to as KMT2A) which encodes a histone methyl-
transferase.  Rearrangements at this site are common in infant AML, with 
different fusion partners having different prognostic significance.  However, in the 
context of tAML, the presence of these commonly seen genetic abnormalities 
help to differentiate tAML from de novo primary AML.  The biology of tAML is 
heterogeneous, but in general it is a difficult-to-treat disease for reasons that will 
be discussed below. 
1.3.2.4 FLT3-ITD AML  FLT3 is a receptor tyrosine kinase encoded by the 
FLT3 gene on chromosome 13.  As mentioned above, FLT3 plays an important 
role in normal hematopoiesis.  Like other receptor tyrosine kinases, FLT3 exists 
primarily as a monomer that upon ligand binding dimerizes and 
autophosphorylates.  This activates an intracellular signaling cascade that has 
consequences for maturation and proliferation.  In approximately 10-20% of 
pediatric AML cases, an internal tandem duplication of variable length (FLT3-
ITD) in exons 14 and 15 promotes ligand-independent activation of FLT3.  The 
unfortunate consequence of this activation is decreased maturation and 
increased proliferation of myeloid progenitor cells.  Similar to FLT3-ITD are point 
mutations in FLT3 that have similar effects, though these mutations are less 
common.  Because FLT3-ITD is not mutually exclusive with other AML subtypes, 
but is instead an additional abnormality, AML FLT3-ITD does not get an 
independent WHO classification.  However, FLT3-ITD status has important 
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prognostic and therapeutic implications and is therefore interrogated as part of 
standard diagnostic workups.  For more information, see the review by Stirewalt 
and Radich [195]. 
1.3.2.5 AML with CEPBA mutation  The CCAAT enhancer binding protein 
family (C/EBP) is made up of several related transcription factors, the α-isoform 
of which (C/EBPα) is commonly mutated in pediatric AML.  These proteins play 
an important role in the differentiation of many tissue types.  Specifically, C/EBPα 
is heavily involved in the maturation of the granulocyte lineage, binding to the 
promoters and supporting transcription of a variety of genes necessary for this 
process.  Mutations in the CEBPA gene in the context of AML result in the 
expression of a 30 kDa form of the C/EBPα protein (full length is approximately 
42 kDa) which functions in a dominant negative fashion to prevent appropriate 
promoter binding and gene transactivation.  Further information can be found in 
the 2009 review by Ho et al.[73]. 
1.3.2.6 AML with NP1 mutation  Nucleophosmin, or NPM1, the protein 
encoded by the NPM1 gene, has pleiotropic functions, but is most known for its 
role as a nuclear chaperone that is involved in the import and export of a wide 
variety of substrates.  When mutated, these functions typically cease, and many 
cellular processes go into disarray.  Mutations in NPM1 are relatively uncommon 
in pediatric AML (up to approximately 10%, 20% in cytogenetically normal AML 
[CN-AML]), however their prevalence increases with patient age.  Importantly for 
AML, NPM1 is involved in hematopoiesis, DNA replication and repair, as well as 
gene transcription.  When mutated, these functions are affected to varying 
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degrees, and NPM1 mutations are considered to be primary events in the 
development of malignancy in some cases.[76,112] 
1.3.2.7 Myeloid proliferations related to Down Syndrome  Down syndrome 
is a commonly occurring genetic abnormality characterized by constitutional 
presence of trisomy 21.  DS is associated with a host of developmental and 
health problems, including a substantially increased risk of developing leukemia.  
The characteristics of DS and associated AML will be discussed in depth in 
section 1.5. 
1.4 Treatment and Prognostic Considerations for Pediatric AML 
When treating AML, there are many factors that need to be considered.  
The first is urgency; AML, especially with certain presentations, is a medical 
emergency that requires immediate intervention.  The second is efficacy; not all 
interventions are equally effective against each disease subtype.  Finally, 
complicating efficacy, is toxicity.  Though advances have been made in the 
treatment of pediatric AML, the most effective therapies are profoundly toxic even 
when administered properly.  Therefore, it is imperative that measures be taken 
to maximize efficacy and minimize toxicity.  Fortunately, years of experience 
have provided many effective treatment protocols, most of which build on a 
framework of induction, consolidation, and, when necessary, salvage and 
transplant. 
1.4.1 Overview  
 When a patient first presents with AML, it is important to reduce their 
leukemic burden.  Acute leukemia causes morbidity for a variety of reasons, but 
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some of the most severe are a direct result of the high burden of rapidly 
proliferating leukemic blasts.  Extremely high white blood cell (WBC) counts, or 
hyperleukocytosis (commonly defined as a WBC count > 100,000 cells/μL), are 
associated with problems directly resulting from the high cellularity of the blood.  
When symptomatic, the condition is called leukostasis.  There are many 
pathologies that contribute to the symptomology of leukostasis, but one of the 
most important is the potentially occlusive nature of the condition.  As a result of 
the high viscosity caused by the relatively rigid circulating blasts, small vessels 
may become occluded by aggregates of WBCs.  This can result in symptoms 
similar to stroke or pulmonary embolism, including respiratory distress and focal 
or generalized neurological deficits.  Other problems at presentation can be bone 
pain, which is believed to be the result of increased pressure in the marrow 
cavities of long bones resulting from hyperproliferation of blasts, and cytopenias.  
As proliferating blasts can overwhelm marrow cavities, it is possible that 
physiologic hematopoiesis is prevented, resulting in deficiencies in other 
compartments.  Common manifestations that result in a patient seeking medical 
care are anemia, which usually presents as fatigue, and thrombocytopenia, 
which usually presents as uncontrollable bleeding or easy bruising.  Alternatively, 
neutropenia can result in severe infection.  
 In order to rapidly decrease the leukemic burden, the patient is treated 
with what is referred to as induction chemotherapy.  Typically given in multiple 
rounds, induction chemotherapy typically consists of moderately high intensity 
dosing schedules.  The goal with induction chemotherapy is to safely induce 
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what is referred to as remission, or undetectable disease (see discussion on 
minimal residual disease [MRD] in section 1.4.3.4), and to allow some restoration 
of normal hematopoiesis.  A patient with newly diagnosed AML is typically very 
ill, and may be less able to tolerate maximal dose chemotherapy, so care must 
be taken to ensure patient safety. 
Once remission is achieved, therapy transitions to a phase known as 
consolidation.  Consolidation therapy is usually maximally intense, both with 
regard to dosing (high doses) and timing (short latency between doses).  The 
goal of consolidation is to eliminate any remaining leukemic blasts, ideally 
resulting in a cure.  Both the duration and types of treatments used for 
consolidation vary between AML subtypes. 
In the event that a patient’s disease does not respond to treatment, and a 
remission cannot be achieved, their disease is considered primary refractory.  
Therapy directed at inducing a remission in refractory disease is often referred to 
as salvage therapy.  Highly variable depending on subtype, salvage therapy 
often consists of somewhat experimental treatments, or treatments that are 
associated with unfavorable side effect profiles that are preferably avoided.  
Similarly, if a patient’s disease that was once in remission returns, it is 
considered to be relapsed.  Relapse, for many AML subtypes, is not uncommon, 
and is associated with varying prognoses.  In the event of relapse, re-induction is 
attempted.  If unsuccessful, the disease is considered secondary refractory.  
When chemotherapy alone is likely to be insufficient to achieve a cure, 
hematopoietic stem cell transplant (HSCT), or bone marrow transplant, may be 
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pursued. 
1.4.2 Prognosis 
 In the past, AML was associated with an almost 100% mortality rate.  
Fortunately, with the discovery of new drugs and improvements in supportive 
care, survival among pediatric AML patients as a group has risen to 
approximately 70%.  With greater treatment experience and understanding of the 
biology underlying AML has come the ability to identify patients that have higher- 
and lower-risk disease.  This has allowed for the use of less aggressive 
treatment in those patients with more favorable prognoses, saving them 
unnecessary toxicity, while still giving appropriate therapies to those whose 
prognoses are more guarded. 
 1.4.2.1 Favorable Prognostic Indicators  There are several disease 
characteristics that are associated with a favorable prognosis (survival >70%).  
Fortunately, CBF AML (t(8;21), t(16;16); inv(16)), which represents one of the 
largest AML subgroups, is associated with a favorable prognosis.  Similarly, APL 
with the standard t(15;17) cytogenetics is also associated with good outcomes.  
Mutations in C/EBPα or NP1 are also positive findings, so long as there is not 
concurrent Flt3 mutation or ITD.  Finally, AML in the DS population is associated 
with one of the most favorable prognoses. 
 1.4.2.2 Adverse Prognostic Indicators  In contrast to those findings listed 
above, there are several cytogenetic or genetic abnormalities associated with 
poorer outcomes (survival <50%).  Certain translocations, including 
t(10;11)(p12;q23), t(6;9)(p23;q34), inv(3)(q21126.2), t(3;3)(q21;q26.2), 
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t(7;12)(q36;p13), t(7;12)(q32;p13), and t(5;11)(q35;p15.5) are poor prognostic 
markers.  Fortunately, these are less common findings.  Though not a specific 
finding, tAML is always considered to have an adverse prognosis.  Finally, 
mutations in Flt3 or Flt3-ITD are less favorable.  When found alone, Flt3 
abnormalities carry an adverse prognosis.  In combination with other, more 
favorable abnormalities, the net result may be intermediate risk, but Flt3 
abnormalities are never favorable prognostic findings. 
 1.3.2.3 Intermediate risk  For many subtypes of AML, prognosis is 
considered to be intermediate (survival 50-70%).  In some cases, this could be 
the result of underlying biology, but often assignment of intermediate risk is due 
to inconclusive results regarding outcome for that specific subtype.  There are 
many findings that have had variable outcomes between trials, and therefore it is 
up to the clinician’s judgment to assign risk and subsequent treatment strategy. 
1.4.3 Treatment of Pediatric AML 
 Though there are many variations on standard treatment for AML, an in 
depth discussion of these variations and their rationale is largely beyond the 
scope of this work.  However, it is important to consider the standards of care 
when investigating new potential therapies, as any interventions will likely be 
given in the context of said therapies or after they have failed.   
 1.4.3.1 Standard Induction and Consolidation  Standard induction therapy 
for pediatric AML has remained largely unchanged for over 20 years, and 
consists of a “3+7” or “3+10” strategy of administering cytarabine (araC) and an 
anthracycline (or substitute), typically daunorubicin (DNR).  Both araC and DNR 
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are genotoxic agents that non-specifically target replicating cells.  An in-depth 
discussion of their mechanisms of action and associated toxicities can be found 
in Chapter 3, but the major toxicities associated with their use can be considered 
to be myelosuppression (araC) and late cardiac toxicity (DNR).  In the typical 
administration schedule, DNR is given at a dose of 45-60 mg/m2 for three days 
and araC is given at a dose of 100-200 mg/m2 for 7 or 10 days, either twice daily 
or via continuous infusion.  This induction can be repeated depending on 
protocol.  Most protocols include a third drug for induction, often etoposide or 
thioguanine.  The evidence supporting these inclusions is, for the most part, non-
conclusive with regards to benefit to overall survival (OS).  If complete remission 
(CR) is obtained, consolidation therapy is appropriate. 
 Consolidation therapy typically consists of high intensity variants of what 
was used during induction.  For most cases, at least two rounds of high-dose 
araC (HiDAC) are given.  The HiDAC course typically consists of several doses 
of araC usually in the range of 1-3 g/m2, usually given every 12 hours for a total 
of <10 doses.  Some protocols treat for 3 consecutive days, while others spread 
out the doses.  In many protocols, dosage is determined at least in part by 
clinical findings.  For most AML subtypes, post-consolidation maintenance 
therapy is inappropriate. 
 Part of every standard therapy protocol should be the administration of 
intrathecal chemotherapy.  Though central nervous system (CNS) involvement is 
uncommon, and CNS relapse does not affect every patient, there is good 
evidence to suggest that administration of intrathecal chemotherapy to every 
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patient greatly reduces the occurrence of these unfavorable events.  Though 
there is a dearth of data suggesting the appropriate intrathecal treatment 
regimen, a combination of methotrexate, araC, and hydrocortisone is considered 
to be likely ideal, and typically between 4 and 12 treatments are given.  It is, 
however, agreed upon that CNS irradiation is inappropriate despite being 
effective, and should not be used in lieu of chemotherapy. 
 1.4.3.2 Role of HSCT  The use of HSCT in the treatment of pediatric AML 
is, in many cases, controversial.  Although HSCT is often considered to be a 
curative therapy, the profound toxicity associated with the procedure prevents its 
use for low-risk disease.  The benefit of HSCT is that the combination of 
extreme-intensity condition regimens and graft-vs-tumor effects are highly 
effective at eradicating disease.  However, the potential for graft-vs-host disease, 
the massive supportive care burden, and risk of mortality associated with HSCT 
are of serious concern.  One of the earliest hurdles that HSCT faces is the 
identification of a suitable donor.  Typically, the ideal donor is an HLA-matched 
sibling, although frequently unrelated donors are required.  Prior to transplant, a 
conditioning regimen of either total body irradiation or myeloablative 
chemotherapy is undergone by the patient.  After conditioning, the cells are 
infused into the patient, but marrow reconstitution can take weeks, assuming 
successful engraftment.  Current recommendations do not allow for HSCT in first 
CR for low-risk patients, but for other patients a risk-benefit analysis is 
appropriate.  Although there has been demonstrated benefit to HSCT for high 
risk patients, treatment related mortality for HSCT in pediatric AML patients is as 
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high as 41%[16]. 
1.4.3.3 Treatment of APL and Flt3-ITD AML  Both APL and Flt3-ITD AML 
present opportunities for treatment with agents that are not commonly used for 
other subtypes of AML.  For the treatment of APL, the use of all-trans retinoic 
acid (ATRA) is the standard of care.  When exposed to ATRA, the PML-RARα 
fusion protein relocalizes and transcription of differentiation-inducing genes is 
increased.  The use of ATRA has helped change APL from being one of the most 
fatal subtypes of AML to one of the most curable.  For the case of Flt3-ITD AML, 
treatment with the multiple tyrosine kinase inhibitor sorafenib offers potential 
benefit.  Early studies have shown favorable results, although the development of 
resistance and cross-resistance to other inhibitors remains problematic[78,219]. 
1.4.3.4  Role of MRD Monitoring  At specific stages of treatment, it is 
important to measure the response to treatment.  Historically, this was performed 
by morphological analysis of bone marrow biopsies/aspirations.  Unfortunately, 
this method is very subjective and offers poor sensitivity for detection of leukemic 
blasts, and MRD negativity was considered <1/50 cells.  However, recent 
advances have allowed for more sensitive and objective methods for the 
detection of residual disease.  In the event that a specific fusion gene or other 
genetic abnormality are identified, PCR detection can be used with a sensitivity 
of approximately 1/10,000 cells.  More useful for most cases, though, is 
multiparameter flow cytometry.  By identifying a patient-specific cell surface 
marker profile, it is possible to rapidly identify as few as 1/1000 cells as leukemic 
blasts for most patients.  The utility of this approach was demonstrated to great 
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effect in the St. Jude AML02 trial, as well as the recent COG-AAML0431 trial. 
[29,175,188,212] 
1.5 Down Syndrome 
 Down syndrome, originally described by John Langdon Down in the latter 
half of the nineteenth century, is a genetic disorder with a host of manifestations.  
Although an in-depth characterization of the health problems and implications for 
care of individuals with DS is beyond the scope of this dissertation, the 
heightened incidence and associated biological mechanisms of AML in this 
population are of great interest and are highly relevant to the presented work. 
1.5.0 Source Material 
 Unless otherwise stated, most of the general background information 
presented below was derived from two excellent overviews of DS ([170,216]) 
1.5.1 Genetics and Incidence of DS 
 In order to conclusively diagnose a patient with DS, their cells must be 
trisomic for chromosome 21.  Though there are less common mechanisms 
leading to trisomy, such as translocations or mosaicism, most cases of DS are 
the result of non-disjunction events at meiosis I of the maternal gamete.  In the 
United States, the incidence of DS in live births is approximately 1 in 1,000.  
Incidence in other countries varies, largely as a result of elective termination of 
prenatally diagnosed pregnancies.  The only well-established risk factor for DS is 
advanced maternal age, as nondisjunction events occur at higher frequencies as 
women age [67].  That being said, there have been efforts to identify modifiable 
risk factors such as folate supplementation [77], although they have been largely 
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met with limited success.   
1.5.2 Health concerns in individuals with DS 
 As mentioned above, individuals with DS are at an elevated risk for a large 
variety of health problems.  The most pervasive concerns in DS patients are 
neurocognitive and psychiatric in nature.  Individuals with DS typically suffer mild 
to moderate cognitive impairment, reaching maximum cognitive ability around 
adolescence.  The difficulties associated with cognitive impairment are frequently 
compounded by psychiatric problems such as attention-deficit hyperactivity 
disorder and depression.  As a result, children with DS need special care that 
can persist well into adulthood, and in some cases the requirement is life-long, 
with only few individuals capable of truly independent living.  Other contributing 
factors to the cognitively impaired phenotype are common anatomical 
abnormalities that inhibit communication abilities.  Individuals with DS commonly 
have structural differences in the systems involved in speech and hearing, such 
as macroglossia and Eustachian tube abnormalities or other conductive 
deficiencies.  These need to be identified early, as difficulties in communication 
can compound the otherwise present cognitive disability.  Additionally, a large 
portion of DS patients have hypothyroidism, which if left untreated can lead to 
further cognitive impairment. 
 There are several commonly encountered health problems in the DS 
population that are especially concerning in the context of leukemia treatment.  
Approximately half of pediatric DS patients have congenital heart defects (CHD) 
of varying severity.  Although not all CHDs require surgical intervention, the 
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already decreased cardiac function at least theoretically puts DS children at an 
increased risk of cardiac dysfunction if treated with cardiotoxic chemotherapy 
regimens.  Another concern results from a combination of anatomical and 
immunological abnormalities that result in an increased risk of infection.  
Structural differences in the both the upper and lower airways of DS patients put 
them at a higher baseline risk for infection.  This is in addition to a lower baseline 
immune function in DS patients.  Though there have not been any individual 
causes of the lowered immune function, it is known that DS patients have below-
average levels of both T- and B-cells. 
 Finally, DS patients have an unusual risk profile for both solid tumors and 
Alzheimer’s disease, though these diseases are of little significance for the 
pediatric DS population.  With the exception of testicular cancer and pediatric 
leukemias, DS patients have lower than expected incidence and mortality rates 
for cancer [66,147,198].  Conversely, the prevalence of Alzheimer’s disease (AD) 
in older DS patients is exceptionally high.  As the life expectancy for individuals 
with DS has increased (median survival is approximately 60 years), so has the 
incidence of diseases that appear later in life, such as AD, which is estimated to 
affect as many as 60% of elderly DS patients [235].  
1.5.3 Leukemia and DS 
 Despite having a lower incidence of solid tumors, the total incidence of 
cancer in the DS population is similar to that in the non-DS population due to the 
increased susceptibility for developing leukemia.  Interestingly, this unusually 
high risk for leukemia is only present in the pediatric DS population and applies 
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to both ALL and AML.  In fact, in a 2005 study, it was found that DS patients 
represented approximately 2% of ALL cases and 14% of AML cases, giving DS 
children an approximately 50-fold greater risk of developing leukemia by age 
5[230].   
 Although this work focuses on AML, it is important to acknowledge the 
unique features of ALL in the DS population.  Unlike non-DS pediatric ALL 
patients, who typically have OS of approximately 80-90%, DS-ALL patients have 
less favorable outcomes (OS approximately 70%).  Their disease also is very 
different from that in the non-DS population in that commonly seen genetic 
abnormalities are rare and almost every DS-ALL case is of the B-precursor cell 
classification, with almost no cases having a T-cell phenotype.  An excellent 
concise review of current DS-ALL treatment and biology can be found in the 
2014 article by Izraeli et al. [89]. 
 1.5.3.1 AML in the Pediatric DS Population  In contrast to the non-DS 
population, AML in the DS population is associated with many unique features.  
DS-AML patients are typically younger than non-DS AML patients, with most 
cases presenting in patients less than four years of age.  Furthermore, 
depending on the study, as many as 100% of pediatric DS-AML patients have a 
megakaryocytic phenotype (FAB M7, AMKL) 
[3,30,45,101,106,161,163,164,175,230,236].  In fact, DS patients have an 
estimated 500-fold increased risk for developing AMKL compared to non-DS 
children [236].  This phenotype is almost universally associated with a somatic 
mutation in the second exon of the GATA1 gene, the significance of which will be 
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discussed below.  Interestingly, GATA1 mutations are found almost exclusively in 
DS-AMKL blasts, with only rare exceptions [2,71,204,215].  Finally, DS-AML 
patients enjoy better prognoses than their non-DS counterparts, with OS of 
approximately 80-90% [3,30,45,101,106,161,163,164,175,230,236].   
 1.5.3.2 Leukemogenesis in DS-AML  Unless otherwise stated, this section 
represents a condensation of information obtained from references [2,13,24-
26,32,71,110,124,172,185,187,204,207,215].  Underlying the features common 
to DS-AML is one of the better understood mechanisms of stepwise 
leukemogenesis.  Likely contributing to both ALL and AML is the effect that 
constitutional trisomy 21 exerts on fetal liver hematopoiesis.  The presence of 
several genes localized to chromosome 21, as well as what is most likely a 
number of currently unknown factors, alters the population distribution and 
growth rates of various hematopoietic progenitors in the fetal liver.   Importantly 
for DS-AML, trisomy 21 appears to give a growth advantage to MEPs, which are 
both more frequent and clonogenic than in non-DS controls.  At this stage, it is 
possible for a cell to develop a mutation in the GATA1 gene, which typically 
causes the transcription of a shorter GATA1s protein, as the result of either 
alternate splicing or transcription start-site utilization.   Lacking the N-terminal 
transactivation domain, but still able to interact with FOG-1, GATA1s prevents 
erythroid differentiation, while also rendering the cell unable to complete 
megakaryocytic differentiation.  The combination of GATA1s and the background 
of trisomy 21 is sufficient to drive a hyper-proliferation of immature 
megakaryoblasts. 
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 The unchecked proliferation on immature megakaryoblasts in the fetus 
can have disastrous complications, occasionally presenting as hydrops fetalis.  
More often, however, this proliferation spontaneously resolves either pre- or 
postnatally.  If detected in an infant, this condition is termed (among other 
names) transient myeloproliferative disorder (TMD).  Whether TMD resolves 
spontaneously or requires treatment (see below), there is a chance that it may 
progress to AMKL.  Interestingly, it has recently been conclusively shown that 
AMKL clones are derived from TMD cells, and that they possess similar 
mutational spectra, albeit at a slightly higher mutational frequency (mean 5.8 
non-silent mutations in AML vs. 1.7 for TMD) [136,229] 
 1.5.3.2 Treatment concerns in DS-AML and TMD  As its name implies, 
TMD is often transient and resolves spontaneously in the majority of cases.  This 
spontaneous resolution has made estimations of incidence difficult, as it has 
been expected that many cases are clinically silent.  A recent study found that, 
surprisingly, almost every DS neonate had circulating blasts, but only 
approximately 20% had detectable GATA1 mutations, indicating TMD[169].  In 
addition to the approximately 20% of TMD patients that progress to AMKL, TMD 
itself is associated with potential complications and may require treatment.  
These typically result from either hyperleukocytosis or organ infiltration by blasts, 
with pancytopenia and hepatic fibrosis being common signs.  In the event of 
symptomatic or complicated disease, low-dose cytarabine may be indicated (1-
3.5 mg/kg/day for 5-7 days)[44]. Overall, TMD is associated with a mortality of 
approximately 20%. 
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As mentioned above, DS-AML is associated with a favorable prognosis 
when compared to non-DS AML.  For reasons that will be discussed in Chapter 3 
of this work, DS-AML cells are known to be more sensitive to chemotherapy; 
however, this is at least partially offset by an increase in sensitivity of non-
leukemia cells in DS patients.  As a result, DS-AML is often successfully treated 
with lower intensity chemotherapy regimens.  For example, the recently finished 
COG AAML043 trial, which focused exclusively on DS-AML, utilized a cumulative 
araC dose of 27,100 mg/m2 araC (Dr. Jeffrey Taub, personal communication), 
whereas the cumulative araC dose for the St. Jude AML02 trial for non-DS AML 
was 45,600 mg/m2 [175].  Though outcomes are generally favorable, those 
patients who either have refractory disease or suffer a relapse have few options 
and poor survival of approximately 25% [119,120,199].  Further complicating 
matters is the poor survival after HSCT, which is only approximately 19% in the 
DS-AML patients [72].  Therefore, advances in care are necessary to better treat 
this group of patients. 
1.6 Why study pediatric DS-AML? 
 It is not difficult to make a Utilitarian argument against research directed at 
improving outcomes for relatively uncommon diseases like DS-AML, or pediatric 
cancers in general.  Though a thorough discussion on the philosophical 
considerations of such research is well beyond the scope of this work, a good 
discussion of the considerations for orphan diseases (which are in many ways 
similar) can be found in the 2005 paper by Gericke, Riesberg, and Busse[54].  
Briefly, it is a fairly commonly held belief that there exists a moral obligation to 
34 
 
 
help every population, regardless of frequency or perceived value to society.  
Furthermore, while gains in overall survival after cancer diagnosis have been 
modest at best, certain subgroups, like those with pediatric cancers, have 
benefited greatly.  For example, 5 year survival after diagnosis with pediatric 
AML has increased from only 19% in 1975 to over 60% today [189].  Moreover, 
the study of relatively rare diseases that affect relatively homogenous 
populations or result from common genetic alterations has guided our 
understanding of some of the most important physiologic and pathological 
processes that are present in the entire population.  Therefore, it is the belief of 
this author that there is merit in studying pediatric AML, especially in the DS 
population, not only for the benefit it may provide to those individuals, but also to 
the population at large.  Finally, the NIH has also developed a plan (available at 
downsydrome.nih.gov) to ensure that adequate research resources are directed 
for DS individuals, a vulnerable patient population due to their multiple medical 
problems. 
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CHAPTER 2 - Overexpression of GATA1 Confers Resistance to 
Chemotherapy in Acute Megakaryocytic Leukemia 
 
2.0 Preface 
 This chapter is taken from a previously published work with the same title 
published in 2013 (PMID 23874683) [18].  It represents a project taken over by 
this author upon joining the lab.  As such, much of the work was done by other 
lab members, including the microarray and ChIP-on-Chip analyses and the work 
leading up to those experiments.  This author was responsible for generation of 
the over-expression clones, validation of the array based experiments, back-end 
analysis of array data, and composing the manuscript.  The figure numbers have 
been adjusted to incorporate what was a supplemental figure in the original 
manuscript.  Finally, the supplemental tables associated with the original 
publication have been omitted from this dissertation as they are especially 
cumbersome and are supplemental in nature.  They can be found on PLoS One’s 
website. 
2.1 Introduction 
In the pediatric population, acute myeloid leukemia has a relatively 
guarded prognosis with five-year survival rates of approximately 50% 
(www.seer.cancer.gov), despite intensive therapy. Acute megakaryocytic 
leukemia (AMKL; M7) is a biologically heterogeneous form of AML, representing 
~10% of pediatric AML cases and 1-2% of adult AML cases [47,166]. AMKL is 
considered a very high-risk subgroup with event-free survival (EFS) rates of 
<35% [5,140]. Remarkably, Down syndrome children with AML, and in particular, 
AMKL, have extremely high EFS rates of approximately 80% [5,45,106,163,236]. 
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The blast cells of DS AMKL patients almost universally harbor a somatic 
mutation in exon 2 of the transcription factor GATA1 gene (localized to Xp11.23), 
resulting in the introduction of premature stop codons and the synthesis of a 
shorter GATA1 protein (designated GATA1s, 40-kDa) initiated from a 
downstream initiation site and distinguishable from the wild-type GATA1 (50-kDa) 
[215].  Both GATA1s and the wild-type GATA1 proteins show similar DNA 
binding abilities and interact with a partner protein named “friend of GATA1” 
(FOG1), though the GATA1s protein exhibits altered transactivation capacity due 
to the loss of the N-terminal activation domain [215]. 
GATA1 is a zinc finger transcription factor that is essential for 
hematopoiesis of the erythrocyte/megakaryocyte lineages. GATA1 acts as an 
activator or repressor of different target genes by forming distinct activating or 
repressive complexes with its partner proteins (reviewed in [32]). The 
pronounced differences in clinical outcomes between DS and non-DS AMKL 
patients and differences in the GATA1 gene mutation status in blast cells suggest 
a potential role for GATA1 in chemotherapy response in both DS and non-DS 
AMKL cases. In the non-DS population, overexpression of GATA1 in 
megakaryoblasts from children with AMKL compared to blasts from children with 
other subtypes of AML was previously observed in gene expression microarray 
studies [171]. Further, earlier studies demonstrated a worse prognosis for AML 
patients (adults without AMKL) whose blast cells expressed higher levels of 
GATA1 than patients whose blasts expressed lower levels of GATA1 [6,186]. 
Collectively, these studies suggest that GATA1 may contribute to chemotherapy 
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resistance via regulation of GATA1 target genes in AML, especially in the AMKL 
subtype. 
Bcl-xL, encoded by the long form splice variant of Bcl-x transcripts which 
counteracts apoptotic signals, may be one of these GATA1 target genes.  Bcl-xL 
is a Bcl-2 family protein that is abundantly expressed in both megakaryocytes 
and erythrocytes (reviewed in [145]). Bcl-xL deficient mice exhibit massive 
apoptosis of fetal liver hematopoietic cells, suggesting that Bcl-xL prevents 
apoptosis of hematopoietic cells [133]. Previous studies have established that 
GATA1 and erythropoietin cooperate to promote erythroid cell survival by 
regulating Bcl-xL expression [58], and that GATA1 is capable of binding and 
activating the Bcl-xL promoter during erythroid differentiation [104]. Thus, it is 
conceivable that GATA1 may also regulate Bcl-xL in megakaryocytes as 
megakaryocytes and erythrocytes are derived from a common progenitor and 
both Bcl-xL and GATA1 are expressed in megakaryocytes.   
In this study, we confirmed the overexpression of GATA1 transcripts in 
non-DS megakaryoblasts compared to non-DS AML blasts. We also 
demonstrated that GATA1 plays critical roles in sensitivities of megakaryocytic 
cells to cytarabine (ara-C) and daunorubicin (DNR), the two main drugs used for 
treating AML, through direct regulation of Bcl-xL. Furthermore, we found that the 
histone deacetylase (HDAC) inhibitor, valproic acid (VPA), can decrease GATA1 
expression and synergize with ara-C in exerting antileukemic activities toward 
megakaryocytic leukemia cells. Using gene-expression microarray and ChIP-on-
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Chip analyses, we identified additional GATA1 target genes which may be 
downstream targets for AMKL treatment.  
2.2 Materials and Methods 
2.2.1 Clinical Samples 
Diagnostic AML blasts (including blasts with the AMKL phenotype) were 
obtained from the Children's Hospital of Michigan leukemia cell bank and from 
the Pediatric Oncology Group 9421 study, as previously described [202]. The 
diagnosis of AMKL was confirmed by flow cytometry detection of the 
megakaryocytic antigens CD41 and CD61. Mononuclear cells were isolated on 
Ficoll-Hypaque gradients to obtain highly purified mononuclear cell fractions 
consisting mostly of leukemic blasts. Written informed consent was provided by 
the parent or legal guardian of the patient according to the Declaration of 
Helsinki. The research protocol was approved by the Human Investigation 
Committee of Wayne State University School of Medicine. 
2.2.2 Cell Culture and Chemotherapy Agents 
The Meg-01 megakaryocytic cell line was obtained from the American 
Type Culture Collection (Manassas, VA). The parental and engineered sublines 
were cultured in RPMI 1640 with 10% fetal bovine serum (FBS) (Hyclone, Logan, 
UT) and 2 mM L-glutamine plus 100 U/ml penicillin and 100 µg/ml streptomycin, 
in a 37°C humidified atmosphere containing 5% CO2/95% air. Ara-C, DNR and 
VPA were purchased from Sigma-Aldrich (St. Louis, MO). 
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2.2.3 shRNA Knockdown of GATA1 in Meg-01 Cells 
GATA1 shRNA lentivirus clones were purchased from the RNAi 
Consortium of Sigma-Aldrich. Meg-01 cells were transduced with the GATA1 
shRNA lentivirus. After selection with puromycin, infected Meg-01 cells were 
plated in soft agar. Colonies were isolated, expanded and assessed for GATA1 
expression by western blotting and real-time RT-PCR. Two clones with 
decreased GATA1 expression (designated GATA1 4-14 and GATA1 5-13) were 
chosen for further study. A pool of cells from the negative control transduction 
(lentivirus expressing a shRNA with limited homology to any known human 
genes) was used as the control (designated GATA1 Neg).  
2.2.4 Quantitation of Gene Expression by Real-time RT-PCR  
Transcripts were quantitated using primers (Table S1) and Sybr Green 
(Roche Diagnostics, Indianapolis, IN) as previously described [53] or Taqman 
probes (Applied Biosystems Inc., Foster City, CA) and a LightCycler real-time 
PCR machine (Roche Diagnostics, Indianapolis, IN) based on the manufacturer’s 
instructions. Real-time PCR experiments were expressed as mean values from 
three independent experiments and normalized to GAPDH, with the exception of 
GATA1 transcript levels post-VPA treatment, which were normalized to RPL13A 
levels as RPL13A has been reported to be a more reliable housekeeping gene 
post-HDAC inhibitor treatment [132]. 
2.2.5 Western Blot Analysis 
Whole cell lysates were prepared by sonication in hypotonic buffer (10 mM 
Tris-Cl, pH 7.0), containing 1% SDS and proteolytic inhibitors, and subjected to 
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SDS-PAGE. Separated proteins were electrophoretically transferred to PVDF 
membranes (Thermo Fisher Inc., Rockford, IL) and immunoblotted with 
antibodies to GATA1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), Bcl-xL 
(Cell Signaling Technology, Danvers, MA), or -actin  (Sigma-Aldrich, St. Louis, 
MO), as described previously [53]. Immunoreactive proteins were visualized 
using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE), as described 
by the manufacturer.  
2.2.6 In Vitro Ara-C and DNR Cytotoxicity Assays 
For determinations of cytotoxicities, the cell lines were cultured in 
complete medium with dialyzed fetal bovine serum in 96-well plates at a density 
of 4 x 104 cells/ml for 96 hours. Cells were cultured continuously with a range of 
ara-C and DNR concentrations at 37 °C, and viable cells were determined using 
the Cell Titer-blue reagent (Promega, Madison, WI) and a fluorescence 
microplate reader. The IC50 values were calculated as the concentrations of drug 
necessary to inhibit 50% growth compared to control cells cultured in the 
absence of drug. The data are presented as the mean values ± standard errors 
from at least 3 independent experiments.  Standard isobologram analysis was 
performed as described previously [225] and combination index (CI) analysis was 
performed using CompuSyn software (ComboSyn, Inc., Paramus, NJ) 
2.2.7 Assessment of Baseline and Drug Induced Apoptosis 
The Meg-01 shRNA stable clones (GATA1 Neg, GATA1 4-14, and GATA1 
5-13) in logarithmic growth phase in RPMI 1640/10% dialyzed FBS in the 
presence or absence of ara-C and VPA were harvested, vigorously pipetted and 
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triplicate samples taken to determine baseline and drug-induced apoptosis using 
the Annexin V-FITC Kit (Beckman Coulter; Brea, CA), as previously described 
[35,225]. Apoptotic events were recorded as a combination of Annexin V+/PI- 
(early apoptotic) and Annexin V+/PI+ (late apoptotic/dead) events. The data are 
presented as mean percentages of Annexin V positive cells ± standard errors 
relative to untreated cells. 
2.2.8 Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assays were performed in Meg-01 cells as previously described [50], 
with GATA1 C-terminus (C-20 antibody, Santa Cruz) antibody or normal IgG. 
Standard PCR for the Bcl-xL promoter region was performed with forward (5’-
gcatccccgcagccacctcctc-3’) and reverse (5’-ccctaaaaattccattccccctccag-3’) 
primers spanning positions –257 to +67. A separate region (exon 3) of the human 
GATA1 gene was also amplified with forward (5’tggagactttgaagacagagcggctgag-
3’) and reverse (5’-gaagcttgggagaggaataggctgctga-3’) primers to validate the 
specificity of the ChIP assays.   
2.2.9 ChIP-on-Chip Assay 
The ChIP-on-Chip protocol was modified from the Agilent Technologies 
Mammalian ChIP-on-Chip Kit protocol at Children’s Hospital of Michigan.  Briefly, 
genomic DNA from the ChIP assay above was incubated with T4 DNA 
polymerase to create blunt ends. Linker DNA was ligated to the blunt end DNA, 
followed by amplification of the samples. The samples were labeled, hybridized 
to the microarray, washed and scanned according to the manufacturer’s protocol.  
Data were imported into Chip Analytics software (v1.3.1, Agilent Technologies) 
42 
 
 
for analysis. Normalization was performed using intra-array lowest and inter-
array median normalizations. Peak detection was performed using the 
Whitehead error model (v1.0) and the Peak Shape Detection algorithm (v2.0). 
Genes with a bound region (peak) were identified, and the associated NCBI 
Refseq accession numbers were used for subsequent analyses.  The ChIP-on-
ChIP results were validated by both regular PCR and real-time PCR (see above). 
We have deposited the raw data at GEO under accession number GSE43018. 
2.2.10 Gene Expression Microarray Analysis 
Gene expression microarray was performed with the Agilent Whole 
Human Genome 4 x 44K microarray (catalog G4112F) at Children’s Hospital of 
Michigan. Microarray sample preparation, hybridization, and data analysis were 
described previously [52]. On each microarray, a labeled GATA1 4-14 or GATA1 
5-13 sample was co-hybridized with an oppositely labeled GATA Neg sample. 
Two arrays were completed for the GATA1 4-14/GATA1 Neg pair and the 
GATA1 5-13/GATA1 Neg pair, respectively, for a total of four arrays. The two 
microarrays used for each clone were hybridized in a “dye swap” arrangement 
with opposite dye orientation to minimize the dye bias effect. Statistical analyses 
were performed using Rosetta Resolver® [159]. We have deposited the raw data 
at GEO under accession number GSE42879 and we confirm all details are 
MIAME compliant.   
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2.2.11 Construction of Plasmids, Transient Transfection, and Luciferase 
Assay 
The GATA1 expression vector, pPacGATA1, and Bcl-x promoter 
construct, pGL3B-Bcl-x-pro, were prepared as previously described [49,51].  D. 
Mel-2 cells (Invitrogen, Carlsbad, CA) were co-transfected with 1 µg of the Bcl-x 
promoter construct and 125 to 500 ng of pPacGATA1 using Fugene 6 reagent 
(Roche, Indianapolis, IN), as described previously [49,51]. Luciferase activities 
were assayed using the Single Luciferase Assay System (Promega) and 
normalized to total cell protein, measured by the Bio-Rad DC-protein assay kit 
(Bio-Rad, Hercules, CA). 
2.2.12 Production of Lentivirus Particles and Transduction  
The pMD-VSV-G and delta 8.2 plasmids were gifts from Dr. Dong at the Tulane 
University. The transfection was carried out by using Lipofectamine and Plus 
reagents (Life Technologies, Carlsbad, CA) according to the manufacturer’s 
instructions. Briefly, RFP (red fluorescent protein) or Bcl-xL cDNA construct from 
Thermo Fisher Scientific Biosciences (Lafayette, CO), pMD-VSV-G and delta 8.2 
were cotransfected into TLA-HEK293T cells and the culture medium was 
harvested 48 h post-transfection. 2x105 cells were transduced overnight by 
adding 1 ml of virus supernatant and 4 µg of polybrene (Sigma-Aldrich).  Cells 
were then triple-washed and allowed to grow for 24-48 hours before addition of 
blasticidin for selection.  Cells were selected for at least 7 days before being 
used for experiments (Invivogen, San Diego, CA). 
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2.2.13 Trypan Blue Exclusion Assay 
An aliquot of the indicated cells was mixed 1:1 with a 0.4% trypan blue solution 
(Sigma-Aldrich, St. Louis, MO) and allowed to incubate for 30 seconds.  The 
mixture was loaded into a haemocytometer and total cell counts, as well as 
trypan blue positive cell counts, were made.  Reported results are the percentage 
of the total cells that were trypan blue positive and represent the average of at 
least three independent counts. 
2.2.14 Statistical Analysis 
Differences in transcript levels between distinct AML patient groups were 
compared using the nonparametric Mann-Whitney two-sample U test. The 
nonparametric Spearman rank correlation coefficient was used to analyze the 
relationship between GATA1 and Bcl-xL transcript levels. Statistical analyses 
were performed with GraphPad Prism 4.0. 
2.3 Results 
2.3.1 Overexpression of GATA1 in AMKL blasts is associated with 
chemotherapy resistance 
To determine if GATA1 is overexpressed in AMKL compared to other 
subtypes of AML in non-DS children, real-time RT-PCR was performed to 
quantify transcript levels of GATA1 in a cohort of diagnostic AML blast samples 
(12 AMKL cases and 31 non-AMKL AML cases). GATA1 transcript levels were 
significantly higher in AMKL blasts compared to blasts of other AML subtypes 
amongst non-DS patients (median 5.5-fold, p=0.004) (Figure 2.1A).   
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To explore the role of GATA1 in chemotherapy sensitivity in AMKL, 
GATA1 expression was knocked-down using lentivirus shRNA in the non-DS 
megakaryocytic cell line Meg-01.  Two stable clones, designated GATA1 4-14 
and GATA1 5-13, showed decreased GATA1 transcripts [~25% relative to a non-
targeted control comprised of a pool of cells infected with a lentivirus negative 
control shRNA (designated GATA1 Neg)], while at the protein level, GATA1 was 
reduced to approximately one-third and one-half that of GATA1 Neg in the GATA 
4-14 and GATA 5-13 clones, respectively (Figures 2.1B&C).  This was 
accompanied by significantly increased baseline apoptosis in both clones relative 
to the GATA1 Neg cells, as measured by flow cytometry with Annexin V-FITC/PI 
staining (Figure 2.1D).  Down-regulation of GATA1 also resulted in increased 
anti-proliferative activity for ara-C and DNR, as measured by the Cell Titer-Blue 
viability assay.  The IC50s for ara-C in the GATA1 Neg, GATA1 4-14, and GATA1 
5-13 were 48.3 nM, 10.8 nM, and 12.0 nM, respectively, while those for DNR 
were 41.6 nM, 27.1 nM, and 18.4 nM, respectively (Figures 2.1E&F).  
2.3.2 Bcl-xL is overexpressed in AMKL and is a GATA1 target gene 
It was previously reported that GATA1 promotes survival of developing 
erythrocytes by upregulating Bcl-xL [58].  On this basis, we hypothesized that 
GATA1 could play a potential role in the survival of AMKL blasts upon treatment 
with cytotoxic agents by upregulating BcL-xL. To begin to test this possibility, Bcl-
xL transcripts were initially measured by real-time RT-PCR in the above cohort of 
31 AMKL and 12 non-AMKL AML cases. Consistent with our hypothesis, Bcl-xL 
transcript levels were significantly higher (median 4.2-fold; p=0.002) in AMKL 
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cases compared to that in other AML subtypes. (Figure 2.3A)  The transcript 
levels of Bcl-xL closely correlated with GATA1 transcripts in AML and AMKL 
blasts (r=0.901, p<0.0001) (Figure 2.3B). Further, in the cell line models, 
knockdown of GATA1 resulted in decreased Bcl-xL expression at both the 
transcript and protein levels (Figures 2C&D). Bcl-2 protein was not detected by 
western blotting in these cells and Mcl-1 levels were comparable to the GATA-1 
Neg cells (Figure 2.2A).  Finally, the sensitivity induced by GATA1 knockdown 
was reduced, at least in part, by exogenous expression of Bcl-xL in the GATA1 
4-14 clone (Figures 2.2B&C) 
To provide evidence that GATA1 directly activates expression of Bcl-xL by 
binding to the putative GATA1 sites in the Bcl-x gene promoter region (Figure 
2.3E), ChIP was performed in Meg-01 cells, followed by PCR of the recovered 
DNA using primers flanking the putative GATA1 binding sites.  As can be seen in 
Figure 2.3F, pulldown with the GATA1-specific antibody GATA1 c-20 resulted in 
specific precipitation of the Bcl-x promoter region (containing the two putative 
GATA1 binding sites) but not an unrelated region. Activation of the Bcl-x 
promoter activity by GATA1 was further confirmed using a luciferase reporter 
assay after cotransfection of D. Mel-2 cells with increasing amounts of a GATA1 
expression vector along with the Bcl-x promoter construct. As shown in Figure 
2.3G, increasing amounts of the GATA1 construct resulted in dose-dependent 
induction of luciferase expression driven by the Bcl-x promoter. Taken together, 
these studies provide direct evidence that GATA1 binds to the GATA1 sites in 
the Bcl-x upstream region and transactivates its activity in Meg-01 cells.  
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2.3.4 Treatment with VPA down-regulated GATA1 and Bcl-xL and sensitized 
Meg-01 cells to ara-C- induced apoptosis  
With currently available treatments, it is not feasible to directly target 
GATA1 in AMKL cells. Based on a previous report [22], we hypothesized that 
treatment with VPA, an HDAC inhibitor, could potentially down-regulate GATA1 
expression. Indeed, treatment of Meg-01 cells with clinically achievable 
concentrations (0.5 and 1.0 mM) of VPA resulted in a reduction in GATA1 protein 
expression, as measured by western blotting (Figure 2.4A), while treatment with 
comparably toxic doses of DNR did not (not shown).  Furthermore, VPA 
treatment also resulted in decreased expression of Bcl-xL protein (Figure 2.4A).  
To investigate the mechanism through which VPA modulates GATA1 expression, 
real time RT-PCR was used to look at GATA1 transcript levels post VPA 
treatment.  Transcript levels were decreased after both 0.5 and 1.0 mM 
treatments, albeit to different degrees (Figure 2.4B). 
To determine the impact of VPA treatment on ara-C cytotoxicity, we 
measured the viability of Meg-01 cells upon exposure to ara-C, along with 
increasing VPA concentrations, using the Cell Titer-Blue viability assay. When 
simultaneously administered with ara-C, VPA at 0.5 and 1 mM significantly 
enhanced ara-C sensitivity (as reflected in decreased IC50s) by 1.6- and 2.7-fold, 
respectively (Figure 2.4C). The combined effects of ara-C with VPA on cell 
proliferation were clearly synergistic, as determined by standard isobologram 
analysis (Figure 3D) and by calculating CI values. A CI<1 (0.83 and 0.81 for the 
combination with 0.5 and 1.0 mM VPA, respectively), indicative of synergism, 
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was calculated for each of the drug combinations. In addition, the combination of 
VPA and ara-C synergistically induced apoptosis as measured by flow cytometry 
with Annexin V-FITC/PI staining (Figure 2.4E).  Exogenous expression of Bcl-xL 
in Meg-01 cells abrogated the enhancement of ara-C cytotoxicity by VPA and 
caused resistance to VPA or ara-C (Figure 2.2B&D) 
2.3.5 Identification of additional GATA1 target genes 
In order to identify additional GATA1 target genes that may contribute to 
chemotherapy resistance, oligonucleotide microarray analyses on RNAs from the 
GATA1 5-13/4-14 clones and GATA1 Neg control were performed. Average log 
ratios, representing the differences in expression between the GATA1 shRNA 
clones and the GATA1 Neg control, were derived for each array feature by 
combining replicate array data, using the error-weighted algorithm of Rosetta 
Resolver®. Differentially expressed genes were identified by their p-values, 
calculated with the Resolver error-model and the replicate data. Using a p-value 
≤ 0.005 as cutoff, 3210 differentially expressed features (probes) were identified, 
with a false discovery rate of 6.4%. Of these, 1521 were down regulated in the 
knockdown clones, while 1689 were upregulated. Validation of the microarray 
results was performed using real-time RT-PCR and separate RNA samples from 
the Meg-01 stable clones. As shown in Figure 2.5A-B, real-time RT-PCR was 
able to validate both up- and down-regulated genes. A full list of differentially 
expressed probes can be found in Tables S2 and S3.  Interestingly, the down-
regulated genes were significantly enriched for genes involved in regulating cell 
division and cell death, and a large number of the upregulated genes were 
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associated with chromatin assembly and organization (Tables S4 and S5, 
respectively), as determined by DAVID gene functional annotation analysis 
[79,80]. 
The above oligonucleotide microarray experiment detected both direct and 
indirect GATA1 target genes in Meg-01 cells. To identify direct targets of GATA1 
among the oligonucleotide microarray gene list, a ChIP-on-Chip experiment was 
performed. Validation of the ChIP-on-Chip analyses was performed using both 
regular PCR and real-time RT-PCR (Figures 2.5C-D). The gene accession 
numbers associated with ChIP-on-Chip peaks (described in methods) were 
compared to the accession numbers for the 3210 differentially expressed genes 
in the GATA1 knockdown clones. The cross-referencing produced a list of 317 
common genes (Figure 2.5E, Table S6) which is likely to be highly enriched for 
bona fide GATA1 target genes. Interestingly, there were many genes in this 
overlapping group that were found by DAVID ontology analysis to be associated 
with either regulation of cell death, cell cycle, or proliferation (Table 2.1.). 
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Figure 2.1  GATA1 transcripts are elevated in AMKL blasts and shRNA knockdown 
increases basal apoptosis and chemotherapy sensitivity.  A: GATA1 transcript levels in 
primary non-AMKL AML or AMKL blasts from non-DS  patients were quantitated by real-time RT-
PCR and normalized to GAPDH transcript levels.  Median transcript levels were compared 
between the two patient groups using the nonparametric Mann-Whitney U test. B-C:  Meg-01 
cells were infected by GATA1 shRNA lentivirus clones.  Colonies were isolated, expanded and 
tested for GATA1 expression by real-time RT-PCR (panel B) and Western blotting (panel C).  
Two colonies (GATA1 4-14 and GATA1 5-13) with decreased GATA1 gene expression were 
selected for further study.  A pool of cells from the negative control infection was used as the 
control (designated GATA1 eg).  D: Baseline apoptosis in the GATA1 4-14, GATA1 5-13 and 
GATA1 Neg was determined by flow cytometry with Annexin V-FITC/PI staining.  *indicates 
p<0.05, error bars indicate standard errors.  E-F: Meg-01 GATA1 shRNA clones were cultured in 
96-well plates at a density of 4x104 cells/mL in the presence of 0-500 nM Ara-C (panel C) or 0-
200 nM DNR (panel D) and cell numbers were determined with the Cell Titer-blue reagent and a 
fluorescence microplate reader.  The data represent mean values ± standard errors from at least 
three independent experiments.   
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Figure 2.3  Bcl-xL is a bona fide GATA1 target gene in AMKL.  A: Bcl-xL transcript levels in 
primary non-AMKL AML or AMKL blasts from non-DS patients were quantified by real-time RT-
PCR.  Median transcript levels were compared between the two patient groups with the use of the 
nonparametric Mann-Whitney U test.  B: The relationship between GATA1 and Bcl-xL transcript 
levels was determined by the nonparametric Spearman rank correlation coefficient.  C: Transcript 
levels for Bcl-xL were quantified by real-time RT-PCR in the Meg-01 shRNA stable clones.  Real-
time PCR results were expressed as mean values from three independent experiments and 
normalized to GAPDH.  D: Whole cell extracts from Meg-01 GATA1 Neg., 4-14 and 5-13 were 
subjected to Western blotting and probed for Bcl-xL and -actin.  E&F:  In vivo binding of GATA1 
to the putative GATA1 binding sites located in the upstream region of the Bcl-x gene in Meg-01 
cells was determined by ChIP assays with the use of regular PCR (panel F), as described in the 
“Materials and Methods”.   The location of the primers used in 2F are indicated by the arrows in 
2E. G: D. Mel-2 cells were transfected with pGL3Basic-Bcl-x-pro along with 0-500 ng of 
pPacGATA1 using the Fugene 6 reagent.  GATA1 transactivation of Bcl-x promoter was 
determined by luciferase reporter gene assays and normalized to total cell protein. 
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Figure 2.4  Valproic acid causes down-regulation of GATA1 and enhances ara-C induced 
apoptosis in Meg-01 cells.  A: Meg-01 cells were treated with VPA for 48h.  Whole cell lysates 
were extracted, subjected to Western blotting and probed by anti-GATA1, Bcl-xL and -actin.  B: 
Meg-01 cells were treated at the indicated dose of VPA for 48h and RNA was harvested for 
quantification of GATA1 transcripts by qRT-PCR.  Transcript levels for GATA1 in the VPA treated 
cells were normalized to untreated cells.  C: Meg-01 cells were treated with ara-C in the presence 
or absence of VPA and viable cell numbers were determined using Cell Titer-blue reagent.  IC50 
values were calculated as the concentration of drug necessary to inhibit 50% proliferation 
compared to control cells cultured in the absence of drug. * indicates p<0.05 D: Standard 
isobologram analysis of Meg-01 cell proliferation inhibition by the combined treatment of ara-C 
and VPA.  The IC50 value for each drug is plotted on the axes; the solid line represents the 
additive effect, while the points represent the concentrations of each drug resulting in 50% 
inhibition of proliferation. Points falling below the line indicate synergism between drug 
combinations whereas those above the line indicate antagonism.  The data are presented as 
mean values ± standard errors from at least 3 independent experiments.  E: Apoptosis after 
indicated treatment for 48 hours as determined by flow cytometry with Annexin V-FITC/PI 
staining.  *indicates p<0.05 relative to no ara-C, error bars indicate standard errors. 
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Figure 2.5  Identification of additional GATA1 target genes.  A&B: Oligonucleotide microarray 
analysis was performed with RNA samples form the Meg-01 shRNA stable clones and the results 
were validated by real-time RT-PCR using Taqman probes.  GATA1-repressed (panel A) and 
GATA1-activated (panel B) transcript levels for MYCN, NCAM1, CD34, ILA1, and EVI1 are 
expressed as mean values from three independent experiments and normalized to GAPDH.  
C&D: ChIP-on-Chip array analysis was performed in Meg-01 cells and the results were validated 
by PCR (panel C) and real-time PCR (panel D) using primers against each region (Table S1). E: 
Overlapping genes between oligonucleotide microarray and ChIP-on-Chip array were identified 
by cross-reference of the two sets of data using GenBank accession numbers.  
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Table 2.1.  Overlapping genes associated with cell-cycle, apoptosis, or 
proliferation 
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2.4 Discussion 
Despite progress in the treatment of AML, there are still AML subtypes 
such as AMKL that have a poor prognosis. Hence, studies examining the basis 
for the relative chemotherapy resistance of these subgroups may lead to 
improvements in therapy. The significantly higher cure rates of DS AMKL 
patients, who almost uniformly harbor somatic mutations in the GATA1 gene, 
suggested that GATA1 may play a critical generalized role in chemotherapy 
response and resistance [5,45,106,163,215,236]. This is also supported by 
studies which established an association between high expression levels of 
GATA1 and a poorer prognosis in adult AML [6,186]. This is particularly relevant 
to non-DS AMKL since overexpression of GATA1 in this AML subtype has been 
previously observed [171]. However, the molecular mechanisms by which 
GATA1 confers chemotherapy resistance in AMKL remain unknown.  
This study established that for patients whose leukemic blasts express 
high levels of GATA1, one potential mechanism of resistance involves 
overexpression of the anti-apoptotic protein Bcl-xL. A direct role for GATA1 in the 
expression of Bcl-xL was implicated by knocking down GATA1 in the 
megakaryocytic cell line, Meg-01.  Upon knocking down GATA1, Bcl-xL 
expression was partially abrogated, accompanied by increased basal apoptosis 
and sensitivity to ara-C and DNR.  Although this finding was not entirely 
unexpected, as the Bcl-2 family proteins are known to inhibit apoptosis and lead 
to chemotherapy resistance, and Bcl-xL has a well-documented role in the 
maintenance of the megakaryocyte lineage [98], it nonetheless suggests a 
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potential target for patients with AMKL. The Bcl-2 family inhibitor GX15-070 is 
currently undergoing clinical trials (www.clinicaltrials.gov) and has shown single 
agent efficacy in leukemia patients [143,182]. 
Another potential approach to enhance the treatment of AML with high 
expression of GATA1 involves the use of HDAC inhibitors, combined with 
standard chemotherapy regimens. While HDAC inhibitors are well known to 
exhibit modest anti-leukemic activities as single agents, preclinical work from our 
group has demonstrated their strong enhancement of standard agents [225,226]. 
In this study, we showed that VPA, an FDA approved anti-epileptic medicine that 
also acts as an HDAC inhibitor, was able to down-regulate GATA1 along with 
Bcl-xL, resulting in synergistic induction of apoptosis upon addition of ara-C.  
Changes in transcript levels post-VPA treatment did not account for the total 
differences in GATA1 protein seen in this study (Figure 3A-B), suggesting that 
VPA affects both the transcriptional and post-transcriptional regulation of GATA1. 
Current clinical trials are investigating the role of HDAC inhibitors as adjuvant 
therapies in many cancers, including pediatric AML (www.clinicaltrials.gov). 
 While Bcl-xL appears to be an important GATA1 target, it was of interest to 
identify additional genes that were regulated either directly or indirectly by 
GATA1. Using gene expression microarray analysis, we were able to identify 
over 3000 genes that were differentially expressed upon GATA1 knockdown 
including genes involved in regulating chromatin structure and cell death.  By 
cross-referencing the differentially expressed genes with regions identified by 
ChIP-on-Chip, we were able to generate a list of 317 genes corresponding to 
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bona fide GATA1 targets.  In addition to these, other potentially important genes 
were identified.  One such gene is DYRK1A, which encodes the dual-specificity 
tyrosine-(Y)-phosphorylation regulated kinase 1A.  This gene was recently 
identified as a driver of megakaryocytic leukemia in a mouse DS AMKL model 
[127]. Neural Cell Adhesion Molecule (NCAM), which was found to be repressed 
by GATA1, is associated with poorer prognosis in AML [162] and early death in 
pediatric AML patients [121]. Vascular endothelial growth factor (VEGF) was 
identified by the ChIP-on-ChIP to be a direct GATA1 target is indicative of poorer 
prognosis [61] and is also a potential therapeutic target in AML [126].  Both Evi1 
and CD34 were found to be activated by GATA1 and could potentially contribute 
to the poorer outcome found in GATA1 overexpressing patients.  Evi1 has been 
found to be epigenetically deregulated and associated with poor prognosis in 
AML [211].  CD34 is a well-established surface marker present on immature 
hematopoietic cells that despite having variable prognostic capacity in mixed 
AML backgrounds [93], is of prognostic significance within some subgroups 
[151,234]. Though not specifically investigated here, this may suggest a potential 
role for the reduction of GATA1 levels in the differentiation induced by HDAC 
inhibitors in AML cells [158]. 
 In summary, in this study we were able to further clarify the role of GATA1 in 
AMKL.  Blasts from patients with AMKL overexpressed GATA1 relative to those 
with other AML subtypes.  The finding that GATA1 is able to bind and activate 
the Bcl-x promoter coupled with the high correlation between GATA1 expression 
and Bcl-xL transcript levels in primary patient samples offers a potential 
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explanation for why AML patients with high GATA1 expression have been found 
to have poorer outcomes.  Furthermore, treatment with the HDAC inhibitor, VPA, 
was shown to decrease both GATA1 and Bcl-xL expression in Meg-01 cells and 
sensitize them to treatment with ara-C.  Finally, by combining gene expression 
microarray and ChIP-on-Chip analyses, we were able to identify additional 
GATA1 target genes to serve as a basis for future studies of both potential 
chemotherapeutic interventions and AMKL biology 
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CHAPTER 3 – Identifying New Therapeutic Options for the Treatment of 
Down Syndrome Acute Myeloid Leukemia 
 
3.0 Preface 
 As discussed in Chapter 1 of this work, there remains a subset of DS-AML 
patients that, despite best clinical efforts, continues to have poor outcomes.  This 
chapter will cover the important background information and preliminary work 
that culminated in the selection of the wee1 inhibitor MK-1775 for further study, 
the results of which are presented in Chapter 4 of this work.  
3.1 Standard Chemotherapeutic Agents for the Treatment of DS-AML 
 In order to effectively design new therapies for the treatment of any 
disease, it is first important to understand the mechanisms by which current 
therapies work (or do not work).  By considering these mechanisms, it is possible 
to focus research efforts on rationally targeted therapies.  The two compounds 
that have formed the backbone of pediatric AML treatment regimens for decades 
are araC and DNR. 
 
Figure 3.1  Chemical structures of araC and DNR 
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3.1.1 araC 
One of the older anticancer drugs, araC was originally modeled after a 
compound first isolated from a marine sponge.  After observing the effects of the 
original “spongothymidine”[11], a cytidine analogue with an arabinose replacing 
the ribose was synthesized and found to have anti-cancer properties[36]. 
3.1.1.1 Incorporation of araC  There are many potential intracellular 
targets for nucleoside analogues, including interruption of signaling cascades, 
metabolic processes, and DNA synthesis and maintenance, with araC targeting 
the last of these.  Itself a pro-drug, araC undergoes stepwise phosphorylation 
inside the cell to become araCTP (see below) and becomes an eligible substrate 
for DNA polymerases.  Despite being initially recognized by the polymerase, as a 
result of its arabinose sugar moiety, araC is a poor substrate for further 
elongation.  Though there have been somewhat contradictory findings with 
regards to the robustness of chain termination after araC incorporation and the 
relative importance of different polymerases, many of these studies were 
performed using either cell-free systems or low-processivity polymerases, 
making the importance of these findings difficult to interpret.  However, it is 
generally agreed upon that araC incorporation levels correlate with and are 
necessary for its toxic effects.[20,46,62,64,88,102,103,144,150,154,167,220] 
 3.1.1.2 Intracellular metabolism of araC  As a nucleoside, the fate of araC 
is regulated by the same enzymes responsible for normal nucleoside 
metabolism.  Predictably, variations in the expression levels of these enzymes 
are some of the best-understood mechanisms of resistance to araC[43,105,129].  
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The main protein believed to be important for araC transport into the cell is the 
human equlibrative nucleoside transporter 1 (hENT1) encoded by the SLC28A1 
gene.  As its name suggests, hENT1 is equilibrative as opposed to concentrative, 
meaning that araC primarily crosses the plasma membrane by a process of 
facilitated diffusion.  Decreased expression of hENT1 has been associated with 
resistance to a variety of nucleoside analogues, including araC, in both AML and 
ALL patients [48,83,192].  Fortunately, there are data to suggest that during 
courses of high-dose araC plasma concentrations reach levels such that araC 
transport is saturated and is no longer limited by hENT1[152,218]. 
 Before intracellular araC can be incorporated into DNA, it must first be 
phosphorylated three times to araC-triphosphate (araCTP).  The first of these 
phosphorylation events is the rate-limiting step, and is catalyzed by the enzyme 
deoxycytidine kinase (dCK).  It has been shown that reductions in dCK activity 
are not only associated with acquired resistance or relapse[12,92], but that 
exogenously induced expression can rescue sensitivity to nucleoside 
analoges[63].  After the initial phosphorylation event, araC is subsequently di- 
and tri-phosphorylated similar to physiologic nucleosides by enzymes that have 
not been associated with chemotherapy sensitivity.   
 Also important for the intracellular levels of araC is the enzyme cytidine 
deaminase (CDA).  Normally involved in pyrimidine salvage, CDA can deaminate 
araC or its phosphorylated derivatives into uracil arabinoside, or araU.  As uracil 
is not a candidate for incorporation into DNA, araU is inactive.  Accordingly, high 
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levels of CDA are associated with nucleoside resistance, while low levels have 
been associated with more favorable outcomes [90,184]. 
3.1.2 DNR and other Topoisomerase II Poisons 
 The mechanism of action of drugs in this class has been surprisingly 
controversial, despite almost constant study since the first isolation of DNR in 
France in 1963 [123].  The biology and relevance to cancer chemotherapy of this 
class of compounds has been reviewed excellently in [55,137,138], from which 
much of this overview has been drawn. 
Daunorubicin belongs first to a class of drugs known as the 
anthracyclines, and then to a larger class known as topoisomerase II (Topo2) 
poisons.  The anthracyclines are all derived from Streptomyces species bacteria 
and share similar chemical structure to each other, as well as the prominent 
anthracycline analogue mitoxantrone.  The other predominant drug in the Topo2 
poison class is etoposide (VP16), which belongs to the class of drugs known as 
epipodophyllotoxins.   
Type-two topoisomerases are responsible for the decatenation of DNA 
after replication.  Unlike type-1 enzymes which cause single strand breaks and 
allow for relaxation of supercoils, type-2 enzymes introduce double strand breaks 
(DSB) in one chain, allowing a second to pass through the gap, followed by 
ligation of the break.   The reason that agents of this class are referred to as 
poisons is that the presence of their target enzyme, either topoisomerase II α or 
β, are required for them to exert their toxic effect.  In fact, expression levels of 
Topo2α have been shown to be major determinants of chemotherapy response 
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[17].   While the exact details are unclear, it is known that Topo2 poisons bind to 
Topo2 and prevent its decatenation activity.  The preponderance of evidence 
suggests that these drugs do this by locking the enzyme in what is referred to as 
a “covalent complex” between it and the newly cleaved DNA.  The result is not 
only a DNA DSB, but also a covalently linked DNA-enzyme complex that is 
difficult to remove.   
3.1.3 Cellular effects of araC and DNR treatment 
 As with most chemotherapeutic treatments, the goal of treating with both 
araC and DNR is to kill the cancer cell, typically through apoptosis.  The exact 
cellular processes that exert these effects are vast, and in many cases are still 
being elucidated.  In general, however, it is believed that these agents induce 
apoptosis primarily by elucidating a DNA-damage response.  Though a thorough 
review of these processes is beyond the scope of this work, (excellent coverage 
of the topic may be found in [7,135,178]), the general trend is that araC induces 
S-phase DNA damage[37] and DNR induces G2- and M-phase DNA 
damage[138].  The first response to DNA damage is typically cell-cycle arrest, 
giving the cell time to repair the damage prior to division or DNA replication.  
However, if the damage is sufficiently severe, the cell undergoes apoptosis.  
Alternatively, damage can go unrepaired with two potential outcomes.  The first is 
the introduction of de novo mutations or chromosomal abnormalities, and the 
second is mitotic catastrophe.  Mitotic catastrophe occurs when cells with 
chromosome-level damage undergo mitosis, resulting in non-standard 
segregation of genetic material.  This is typically incompatible with further growth 
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and results in cell death.  However, in either case, if the cell does not die, the 
altered genetic material is then passed along to the next generation. 
3.1.4 Toxicities of araC and DNR 
 3.1.3.1 Toxicity of therapy with araC  Despite being the primary backbone 
of most therapeutic regimens, araC treatment is associated with profound 
toxicity.  Most patients suffer substantial myelosuppression, resulting in 
neutropenia, thrombocytopenia, and anemia.  While thrombocytopenia and 
anemia are treatable with transfusion if necessary, neutropenia is not.  
Neutropenic patients are at a substantially elevated risk for infection, and 
prophylactic antibiotics directed against both bacteria and fungi are now being 
used more commonly as supportive care in leukemia protocols.  Other adverse 
effects include corneal toxicity, which can be managed prophylactically with 
steroid eye-drops, and common chemotherapy side effects like alopecia, nausea, 
and gastrointestinal toxicity. [75,173] 
 3.1.3.2 Toxicity of therapy specific to DNR  When considering 
chemotherapy with Topo2 poisons, there are two specific late effects that are of 
special note.  The first is an elevated risk of secondary malignancy, specifically 
tAML.  Though secondary malignancy is a risk of any DNA damaging 
chemotherapeutic agent, Topo2 poisons (especially VP16) have been associated 
with a greatly enhanced risk of tAML[39,148].  The second is the well-established 
risk for cardiotoxicity (e.g. decreased left ventricular function) after treatment with 
anthracyclines.  Cardiotoxicity can manifest either early (within one year) [100] or 
late [84,228], and though not all cardiotoxicity in cancer survivors is related to 
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anthracyclines [113], it is still concerning such that anthracycline administration is 
typically limited by lifetime cumulative doses. 
 While the effects of Topo2 poisons on secondary malignancy incidence 
are considered undesirable on-target effects, there is much debate as to the 
underlying mechanism behind the cardiotoxic effects of anthracyclines.  Early 
work in this field showed that anthracyclines were able to redox cycle due to their 
quinone moiety, and that this effect was especially prominent in the presence of 
iron.  These findings lead to the belief that anthracyclines exerted their toxic 
effects through reactive oxygen species- (ROS) mediated damage.  A 
consequence of this belief was that investigators designed iron-chelators to help 
protect cardiac tissue from ROS generation, one of which was dexrazoxane.  
Interestingly, dexrazoxane has been shown to also catalytically inhibit Topo2, 
which could theoretically block the activity of Topo2 poisons [55,137,138].  The 
debate regarding the mechanism of cardiac toxicity still continues, with recent 
studies pointing at on-target effects of anthracyclines and their action on Topo2β 
as well as mitochondrial iron accumulation in cardiac tissue [86,231].  
Furthermore, while recent clinical studies have shown benefit of dexrazoxane 
adjuvant therapy [114], other studies have associated its use with an increased 
incidence of tAML[176,205], and the FDA has since changed its approval to only 
apply to adult breast cancer patients who have received high doses of 
anthracycline (www.FDA.gov). 
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3.2 Chemotherapy sensitivity in DS patients 
 As mentioned in Chapter 1 of this work, DS-AML patients have a unique 
response to chemotherapy compared to non-DS patients.  Most importantly, it 
has been shown that leukemic blasts from DS patients are more sensitive to 
chemotherapy.  Two studies from this group demonstrated that DS-AML blasts 
generate higher levels of the active araC metabolite araCTP[202,203].    This 
was at least partially due to increased expression levels of cystathionine-β-
synthase (CBS), which is located on chromosome 21.  Increased CBS 
expression impacts the folate cycling pathways involved in nucleoside pool 
maintenance thereby decreasing the intracellular pools of dCTP.  As dCTP 
inhibits the araC-activating enzyme dCK, elevated CBS levels have been shown 
to correlate with araCTP levels and increase survival in an in vivo mouse 
xenograft leukemia model[201,202]. A 1999 study replicated these findings, 
showing that DS-AML blasts were more sensitive to both araC and doxorubicin 
(an anthracycline like DNR), but that this trend did not hold true for DS-ALL 
blasts[42].  Another mechanism contributing to this sensitivity is the impact of 
GATA1 mutations in DS-AML on CDA expression.  Two studies from this group 
demonstrated that CDA is a GATA1-target gene, and that GATA1s mutants are 
less-capable of activating CDA expression, resulting in higher araCTP levels and 
higher sensitivity to araC[51,53].  Further, more recent work from this group has 
demonstrated that DS-AML has a unique gene expression profile compared to 
non-DS-AML, and that GATA1s also has positive functions promoting the growth 
and survival of DS-AML blasts[49,222]. 
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 The increased sensitivity of DS-AML blasts to chemotherapy, 
unfortunately, also extends to DS-AML patients, who are at a greater risk for 
treatment related toxicity.  In addition to being more susceptible to infection at 
baseline as a result of having DS, DS-AML patients have historically suffered 
from increased treatment-related mortality secondary to infectious complications, 
although more recent protocols have seen greater success at avoiding these 
unfavorable outcomes[44,106,161].  Of special concern is anthracycline use in 
this population.  At least partially as a result of the high incidence of congenital 
heart defects in this population, DS patients are more likely to develop 
cardiotoxicity, and it that toxicity which may be lethal[100,142]. 
3.3 Identifying new therapies for DS-AML – approach 
 In order to further improve outcomes for DS-AML patients, new 
therapeutic approaches must be developed.  As mentioned in Chapter 1, there 
are subsets of DS-AML patients who have poor outcomes, and transplant is not 
an attractive option in the DS-AML population.  Furthermore, toxicity continues to 
be a concern for these patients.  With the goal of this study being to identify new 
chemotherapeutic options, a careful approach to maximize the clinical potential 
of our findings was important. 
 The first important consideration is that any results obtained should be as 
rapidly translatable to the clinic as possible.  Though there are exciting options 
emerging from early-stage investigational drugs, agents that are not already 
under clinical study are less likely to be tested in the DS population even in the 
distant future.  Therefore, we set out to provide a foundation supporting the 
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immediate inclusion of new agents into DS-AML treatment protocols upon the 
approval of drugs currently under investigation for other patient groups.  
Moreover, this limits the investigation to agents that show effects within clinically 
achievable concentration ranges.  Finally, as a result of responsible clinical study 
design, any agents selected for study must show at least additive effects with 
araC, as it is unlikely that study arms would withhold this standard of care agent. 
 The rest of the considerations driving agent selection are of a more 
practical nature.  Though there has been much recent progress in the field of 
oncology with regards to biologic therapies (e.g. antibodies and other 
immunotherapies) these treatments are difficult to interrogate in vitro using our 
model system (see below).  Also important was that any compound tested 
needed to be available.  Finally, agents were chosen in a way that was perceived 
to minimize the replication of effort such that either knowledge or perception of 
extensive study by either collaborators or outside groups precluded inclusion in 
this study. 
3.4 Cell line models 
 In order to begin investigations into new therapeutic options for DS-AML, 
model systems needed to be utilized as primary research in patients is neither 
feasible nor ethical.  The model systems used herein are two DS-AML cell lines, 
derived from DS children with AMKL.  The first, CMK, was derived from a patient 
who presented first with sensitive disease but unfortunately suffered a relapse 
[181].  The second, CMY was derived from a patient who suffered from primary 
refractory disease [131].  Though both of these cell lines harbor p53 defects that 
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were not present in the primary disease, they are both of the AMKL phenotype 
with confirmed GATA1 mutations, and are thus reputable cell line models. 
3.4.1 Initial characterization of DS-AML cell lines 
 The first step in characterizing the CMK and CMY cell line models was 
determining their response to the standard chemotherapeutic agents, araC and 
DNR.  Utilizing a 3-day 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay (methods described in Chapter 4), it was found that CMY 
was significantly more resistant to both agents than was CMK (Figure 3.2A).  
Because both araC and DNR are cell-cycle phase dependent (S- and G2/M, 
respectively), the proliferation rate of the two cell lines was determined by serial 
cell counts for 3 days.  It was found that CMY does in fact proliferate more slowly 
than CMK (doubling time 33 vs 22 hours) (Figure 3.2B).  Next, the expression 
levels of proteins associated with araC and DNR sensitivity (hENT1, dCK, 
Topo2α), as well as Bcl-2 family proteins associated with resistance to apoptosis 
(reviewed in [33]), were interrogated via western blot.  Because expression of 
Bcl-2 family proteins are thought to be able to compensate for one another, it 
was found that the only substantial difference was in the expression of Topo2α, 
which was lower in CMY (Figure 3.2C).  Finally, it was of interest to determine 
the response of CMK and CMY cells to treatment with additional agents already 
under investigation to determine if the relative resistance to araC and DNR was 
due to CMY cells being globally more resistant or if the resistance was specific to 
those two classes of agents (Figure 3.2D).  Again using a 3-day MTT assay, it 
was shown that CMY displayed class-wide resistance to the nucleoside 
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analogues araC, clofarabine, and decitabine, as well as to the Topo2 poisons 
DNR, etoposide, and mitoxantrone.  This class-wide resistance to the Topo2 
poisons was not unexpected, as CMY cells possess lower levels of the target 
protein Topo2α (Figure 3.2C).  Interestingly, no cross-resistance was observed 
for the HDAC inhibitors vorinostat (also known as suberanilohydroxamic acid, 
SAHA), panobinostat (also known as LBH-589) and mocetinostat (also known as 
MGCD0103).  Similarly, there was no difference in sensitivity to the multiple 
kinase inhibitor sorafenib.  Interestingly, CMY was actually more sensitive to the 
proteasome inhibitor bortezomib (also known as velcade) than CMK, although it 
is difficult to make a claim for biological significance with only a 2 nM difference 
in IC50s.  Based on these results, it was determined that CMY is not globally 
resistant to all treatments compared to CMK, and that it would be possible to find 
an agent that may be similarly effective in resistant and sensitive cases. 
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Figure 3.2  Initial characterization of the CMK and CMY cell lines.  A: CMY cells are more 
resistant to both araC and DNR than CMK cells as measured by 72 hour MTT assay.  B:  CMK 
and CMY cells were plated at similar densities and counted every day while the cells remained in 
logarithmic phase growth.  Error bars represent standard error on the mean values from three 
independent experiments.  C:  Expression levels of the indicated proteins were interrogated using 
western blots on lysates from untreated, logarithmically growing cells.  Representative images are 
shown.  D:  The sensitivities to the indicated agents of both CMK and CMY cells as measured by 
72 hour MTT assays.   
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3.4  Identifying new agents 
From the results shown in Figure 3.2, it was determined that it is unlikely that 
either nucleoside analogues or topoisomerase poisons would likely produce 
favorable results.  Because araC requires cells to be in S-phase for it to exert its 
toxic effects, agents that have shown promise in other studies but cause 
proliferative arrest, like cyclin dependent kinase (CDK) inhibitors and rapalogues, 
were not eligible for consideration in this study.  It was hypothesized that agents 
that either targeted cells post-S phase or cell cycle checkpoints could be very 
promising, especially given the pre-clinical successes of Chk1 inhibitors[19,34].  
The four targets chosen for further study were the aurora kinases A and B, polo-
like kinase (Plk)1, and the wee1 kinase.  The first three of these will be covered 
in this chapter, while the results concerning wee1 can be found in Chapter 4 of 
this work. 
3.4.1 Aurora kinases A and B and Plk1 
 In recent years, the aurora kinases and Plk1 have been the subject of 
great clinical interest for the treatment of malignancy.  Studies have shown that 
the aurora A and B kinases as well as Plk1 are overexpressed in AML cells, 
compared to normal bone marrow cells[65,81,87,165].  Furthermore, preclinical 
work demonstrated a favorable effect of inhibitors of these kinases on AML cell 
lines and primary AML blasts, in in vivo, ex vivo, and in vitro 
experiments[57,65,81,87,97,165,227].  Thus, it is important to understand the 
mechanism of action of these kinases, as well as the effect their inhibition has on 
proliferation. 
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3.4.1.1 Functions of the Aurora A and B kinases and Plk1  The general 
role played by these kinases is the regulation of the transition between  the G2 
phase of the cell cycle and subsequent mitotic processes (For excellent reviews 
on the functions of these proteins, see the reviews by Lens et al., Stebhardt, 
Goldenssn and Crispino, and Farag [38,56,109,197]).  After a cell has finished 
replicating its DNA, preparations are made to allow for successful completion of 
mitosis.  The processes underlying mitosis are extremely complicated, but there 
are some major milestones that must be met in order to ensure that proper 
segregation of genetic material and formation of the proper number of daughter 
cells occurs.  For the purposes of this discussion, emphasis will be placed on the 
successful alignment of chromosomes at the metaphase plate and the formation 
of a bipolar spindle assembly.   
 Under normal conditions, after replication, cells are free to enter into 
mitosis even in the absence of aurora A kinase and Plk1.  However, in the 
presence of G2 checkpoint activation, these proteins become necessary for 
further cell cycle progression [116,125,209].  Normally, CDK1 activity is high after 
S-phase, and in combination with its partner cyclin B, it phosphorylates a host of 
targets required for mitotic entry.  However, in the presence of checkpoint 
activation, the inhibitory phosphorylation on CDK1 provided by the wee1 kinase 
is not effectively removed, preventing mitotic entry.  To progress, aurora A kinase 
activates Plk1, which subsequently phosphorylates wee1, leading to its 
degradation[213] and allows for an increase in CDK1 activity.  This starts a feed-
forward loop in which CDK1 further activates aurora A kinase and Plk1, allowing 
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for mitotic entry.  In contrast, aurora B kinase is not required for mitotic entry, 
although, interestingly, inhibition during interphase is capable of disrupting 
normal mitotic chromosomal organization[68].  After mitotic entry, aurora A 
kinase and Plk1 cooperate to form a bipolar spindle assembly while aurora B 
kinase and Plk1 cooperate to regulate chromatid cohesion and 
chromosome/microtubule interactions.  Following initiation of anaphase, all three 
proteins begin degradation and mitosis completes[109].  
 Inhibition or down-regulation of these kinases causes interesting, albeit 
complicated effects.  Aurora A kinase inhibition rapidly leads to aneuploidy 
secondary to ineffective spindle formation and chromosome segregation 
[74,128].  Aurora B kinase inhibition, on the other hand, leads to bypass of mitotic 
arrest and tetraploidy, with the potential for further genetic replication, although 
apoptosis is the likely outcome[91].  Contrary to both of these, is the result of 
Plk1 inhibition, which leads to robust arrest in early mitosis and subsequent 
mitotic death[193]. 
3.4.1.2 Introduction to inhibitors used in this study  When studying the 
effects of inhibiting kinases, results are only as reliable as inhibitors are specific.  
Fortunately, specific inhibitors for all three of these kinases have not only been 
developed, but are in early-stage clinical trials, so some pharmacokinetic data 
are available.  To inhibit Plk1, the compound BI6727 was used.  This agent has 
been shown to be safe in phase 1 and 2 clinical trials, with maximal plasma 
concentrations exceeding 1 μM, although in the more recent study the Cmax was 
only approximately 400 nM[183,191].  It is worth noting, however, that at the 
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conclusion of the Phase 2 trial, it was determined that BI6727 did not have 
sufficient single-agent activity against urothelial cell carcinomas to be further 
pursued as a single agent[191]. 
 Barasertib, also known as AZD1152, is a selective aurora B kinase 
inhibitor.  A pro-drug, AZD1152 is converted in vivo to the active form AZD1152-
HQPA, which has been shown to be safe and possibly effective for elderly 
patients with advanced AML[94,95,122].  The half-life of this compound is 
prolonged, at approximately 77 hours, but its maximum plasma concentration is 
relatively low, approximately 400-500 nM when used alone[94,122], and only 
approximately 300 nM in the presence of low-dose araC[95]. 
 Finally, alisertib, or MLN8237, is an orally-dosed selective inhibitor of 
aurora A kinase.  Early results have been published for studies investigating the 
use of this agent in both lymphomas and advanced solid tumors[21,41].  In both 
studies, MLN8237 was tolerated, showed promising efficacy, and had maximal 
plasma concentrations between 1 and 2 μM, with a half-life on the order of 15 
hours[21,41].  Importantly, MLN8237 was identified in pre-clinical studies by John 
Crispino’s group to be especially promising for the treatment of DS-AMKL, as it 
was shown to induce polyploidization and differentiation of CMK cells as well as 
non-DS AMKL blasts[217]. 
3.5  Effect of aurora kinase and Plk1 inhibition on araC sensitivity in CMK 
and CMY  
 In order to begin investigations of the effects of aurora and polo-like 
kinase inhibition on the araC sensitivities of CMK and CMY cells, standard 3 day 
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MTT was performed to determine the appropriate concentration ranges for these 
agents for combination study.  Concentration ranges were initially chosen based 
on preliminary results from clinical trials, with the goal that concentrations that 
were not clinically relevant would not be pursued.  The only agent for which this 
was problematic was AZD1152-HQPA, as CMY cells were relatively insensitive 
to this drug at clinically achievable concentrations (see Figure 3.4).  However, 
only minor increases over what is clinically relevant (1,000 nM) were required to 
generate appropriate response curves.   
After identification of the proper concentration range, the effect of the 
combination of araC and the inhibitor of interest was determined again using 3-
day MTT.  The effects of the single drugs on CMK and CMY cells could be 
compared readily by their respective IC50s, but comparison of their interactions 
with araC required further analysis.   
In order to compare the combined effects, standard isobolograms and 
combination indices (CIs) were used.  Isobolograms represent a simple 
visualization that takes into account the desired parameter (in this case IC50) for 
each drug and allows for quick assessment of the nature of the effect of the drug 
combination.  Each axis represents the concentration of the indicated drug.  Any 
combination that lies below the line connecting the points representing the IC50 of 
both drugs is considered to be “synergistic”, those on the line are considered 
“additive”, and those above the line are considered “antagonistic”.  It is important 
to recognize that for a given isobologram, a desired effect level must be pre-
determined.  For these cases, an effect of 50% viability compared to untreated 
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cells was used.  The same range of araC was tested in the presence of no 
additional drug, and three increasing concentrations of the second drug, so each 
plot has 5 total points: each drug alone, and the three points representing the 
araC concentration required to inhibit 50% of cell growth in the presence of the 
given secondary drug concentration.  For the isobolograms presented in this 
section, the axes were normalized to the IC50 for each drug such that it was equal 
to 1.  The benefit of this approach is two-fold: it allows for better visualization of 
reproducibility, since each combination point gets both X and Y error bars, and it 
makes visual comparison between the two cell lines more direct.  Alternatively, 
synergy can be calculated using the median-effect principle from Chou and 
Talalay.  In this system, a CI < 1 indicates “synergy”, CI > 1 indicates 
“antagonism”, and a CI of 1 indicates “additivity”.  For a comprehensive review of 
the principles of designating synergy in drug combination studies, see Chou’s 
2006 review [27].  CIs were determined using the CompuSyn software. 
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Figure 3.3  CIs for the combination with araC.  The CIs representing each point on the 
isobolograms in Figures 3.4-3.6 are plotted, with each point here representing an individual trial.  
The CIs were compared to a theoretical median of 1.0 (indicating additivity) using the Wilcoxon 
Signed Rank Test; p-values and results can be found in the text. 
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Figure 3.4  The combination of AZD1152-HQPA and araC in CMK and CMY cells.  A:  The 
chemical structure of AZD1152-HQPA.  B:  The effect of AZD1152-HQPA on the percent of 
viable CMK and CMY cells as measured by 3-day MTT assay.  Data points represent average 
values from 3 independent experiments while error bars represent standard error of the mean.  C 
and D:  Normalized standard isobologram analysis of the interactions between araC and 
AZD1152-HQPA on cell viability.  Each axis represents the concentration relative to the IC50 of 
that drug, which was normalized to 1.0.  Each point represents the average value from 3 
independent experiments, with error bars representing standard error of the mean.  X-error bars 
represent mostly variation in the IC50 of AZD1152-HQPA, while Y-error bars represent variation in 
both the combined effect of both drugs as well as the variation in the IC50 of araC. 
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Figure 3.5  The combination of MLN8237 and araC in CMK and CMY cells.  A:  The chemical 
structure of MLN8237.  B:  The effect of MLN8237 on the percent of viable CMK and CMY cells 
as measured by 3-day MTT assay.  Data points represent average values from 3 independent 
experiments while error bars represent standard error of the mean.  C and D:  Normalized 
standard isobologram analysis of the interactions between araC and MLN8237 on cell viability.  
Each axis represents the concentration relative to the IC50 of that drug, which was normalized to 
1.0.  Each point represents the average value from 3 independent experiments, with error bars 
representing standard error of the mean.  X-error bars represent mostly variation in the IC50 of 
MLN8237, while Y-error bars represent variation in both the combined effect of both drugs as well 
as the variation in the IC50 of araC. 
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Figure 3.6  The combination of BI6727 and araC in CMK and CMY cells.  A:  The chemical 
structure of BI6727.  B:  The effect of BI6727 on the percent of viable CMK and CMY cells as 
measured by 3-day MTT assay.  Data points represent average values from 3 independent 
experiments while error bars represent standard error of the mean.  C and D:  Normalized 
standard isobologram analysis of the interactions between araC and BI6727on cell viability.  Each 
axis represents the concentration relative to the IC50 of that drug, which was normalized to 1.0.  
Each point represents the average value from 3 independent experiments, with error bars 
representing standard error of the mean.  X-error bars represent mostly variation in the IC50 of 
BI6727, while Y-error bars represent variation in both the combined effect of both drugs as well 
as the variation in the IC50 of araC. 
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3.5.1  The combination of AZD1152-HQPA and araC in CMK and CMY cells 
As seen in Figure 3.4B, CMK and CMY cells displayed different sensitivity 
to the aurora B kinase inhibitor AZD1152-HQPA, with IC50s of 183 nM (95% 151-
216nM) and 689 nM (95% 652-725 nM), respectively.  Respecting the maximally 
achievable plasma concentration of 300-400 nM, combination doses tested were 
lower relative to the IC50 of CMY than CMK due to the relative insensitivity of 
CMY cells to AZD1152-HQPA (Figure 3.3C-D).  It can be seen that the effect of 
the combination of araC and AZD1152-HQPA trended towards additivity with 
CMK demonstrating slight antagonism and CMY showing slight synergism.  This 
relationship was similarly seen when CI was used as the metric (Figure 3.3).  For 
both cell lines, their CIs (median 1.1 and 0.87 for CMK and CMY, respectively) 
were found to be significantly different than a theoretical median of 1.0 by the 
Wilcoxon Signed Rank test (p=0.02 for both cell lines).   
3.5.2  The combination of MLN8237 and araC in CMK and CMY cells 
As seen in Figure 3.5B, CMK and CMY displayed different sensitivities to 
the aurora A kinase inhibitor MLN8237, with IC50s of 19 nM (95% 16-23nM) and 
40 nM (95% 29-53 nM), respectively.  Though this difference is relatively large 
(approximately 2-fold), it is possibly insignificant given the achievable plasma 
concentrations exceeding 1 μM [21,41].  In contrast to the response seen for the 
combination of araC and AZD1152-HQPA, both CMK and CMY demonstrated an 
additive-to-antagonistic response to this combination (Figure 3.5C and D).   
When using CI to determine the nature of the interaction between MLN8237 and 
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araC (Figure 3.3), only those for CMY (median 1.3, vs 1.1 for CMK) were found 
to be significantly different than a theoretical median of 1.0 (p=0.01 and 0.16 for 
CMY and CMK, respectively).   
3.5.3  The combination of BI6727 and araC in CMK and CMY cells 
As seen in Figure 3.6B, CMK and CMY were differentially sensitive to 
BI6727, although interestingly, CMK was the more resistant cell line in this case.  
CMK and CMY had IC50s of 50 nM (95% 38-62nM) and 30 nM (95% 23-36 nM), 
respectively.  Similar to both AZD1152-HQPA and MLN8237, the isobologram 
analyses (Figure 3.6C and D) did not appear to display any synergism between 
araC and BI6727, instead trending towards antagonism.  In fact, the CIs for these 
interactions were both found to significantly differ from a theoretical median of 1.0 
(CI 1.1, p=0.02 and CI 1.2, p=.008 for CMK and CMY, respectively). 
3.6 Discussion 
 Unfortunately, despite promising preclinical and clinical findings 
[14,21,41,74,81,87,91,94,95,122,128,183,191,193,217], AZD1152-HQPA, 
MLN8237, and BI6727 all lacked promise in these preliminary studies.  While all 
three agents demonstrated single-agent efficacy at clinically achievable 
concentrations in the CMK cell line, only MLN8237 and BI6727 were effective in 
CMY cells.  Furthermore, the combination of these agents with araC resulted in 
additive-to-antagonistic interactions in each case.   
 Although these agents were not chosen for further investigation in this 
study, it is not to say that there is no potential place for them in the clinical setting 
for the treatment of DS-AML.  It is certainly possible that the design of this study 
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was not optimal to demonstrate a favorable effect of these agents.  One potential 
cause may have been the selection of the 3-day time point.  It may be the case 
that had these experiments been terminated at 48 or 96 hours, different results 
would have been found, however, the 72 hour time point yielded reproducible 
results for araC treatment and was thus used here.  It is also possible that had a 
different effect level been interrogated (e.g. IC75 or IC90), a different trend may 
have emerged.  While the utility of higher effect levels in investigating 
chemotherapy drug effects can definitely be argued, it is the opinion of this 
author that when using in vitro cell line models, IC50 is more typically 
communicated in the literature and is therefore a better endpoint for these 
preliminary-type studies.  Further, the experiments presented above were 
designed around finding a 50% effect size; therefore the concentration ranges 
tested did not produce results suitable for analysis at higher effect levels, 
prohibiting robust post-hoc analyses.  It is worth noting that, in the context of in 
vivo models, the utility of higher effect levels is much greater, as typically the goal 
of treatment is disease eradication, not simply a 50% reduction in tumor burden. 
 In contrast to these agents, which did meet not the relatively strict criteria 
for further study, a first-in-class inhibitor of the wee1 kinase, MK-1775, did in fact 
demonstrate favorable effect.  The results of the preliminary studies with MK-
1775, as well as a further characterization of the mechanism of its effect in DS-
AML cells are found in the next chapter of this work.    
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CHAPTER 4 - Targeting the wee1 Kinase for Treatment of Pediatric Down 
Syndrome Acute Myeloid Leukemia 
 
4.0 Preface 
 This chapter is taken in its entirety from a manuscript recently accepted by 
the journal Pediatric Blood & Cancer.  Though the text will likely be almost 
identical to the final published copy, figure numbering has been adjusted to 
conform to dissertation standards.  What was originally an online supplement has 
been incorporated into this work.  This author was responsible for the design and 
execution of all experiments described herein, with the exception of the ex vivo 
experiment presented in Figures 4.3F (designed by this author, performed by 
Holly Pitman) and the flow cytometry experiments, which were designed, set up, 
and analyzed by this author but the steps involving the cytometer were 
performed by Steve Buck. 
4.1 Introduction 
Pediatric acute myeloid leukemia (AML) remains a difficult disease to treat and is 
associated with a relatively guarded prognosis.  Patients with Down syndrome 
(DS), however, typically have much better outcomes, despite having an 
increased risk of developing AML[223].  This is due to enhanced sensitivity to 
cytarabine (araC) and daunorubicin imparted by the unique biology of AML in the 
DS population (DS-AML), in which most cases are the megakaryocytic (AMKL) 
subtype and have somatic mutations in the X-linked transcription factor GATA1 
gene[51,53,201,203,215].   
 Despite favorable outcomes, there are still challenges in treating this 
group of children.  Patients with DS-AML who experience either an induction 
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failure or relapse have dismal prognoses and very few options for 
salvage[119,120,199].  DS patients with relapsed AML treated on the Pediatric 
Oncology Group (POG) 9421 and Children’s Cancer Group (CCG)-2891 AML 
studies had an overall survival (OS) rate of 12%, while a Japanese study 
reported an OS of 25.9% for relapsed and refractory DS AML patients[118,200]. 
DS-AML patients experience greater adverse toxicity, preventing the use of 
higher chemotherapy doses, and the high prevalence of congenital heart defects 
in the DS population makes anthracycline use especially 
challenging[100,107,141,161]. Following stem cell transplants (SCT), DS-AML 
patients only had an OS of 19% [72]. These studies all highlight that DS patients 
with refractory/relapsed AML have extremely chemotherapy-resistant disease. 
Thus, there is a clinical need for more effective therapies to be developed to treat 
this subgroup of DS-AML patients. 
 Inhibition of the wee1 kinase has recently been identified as a potential 
option for the treatment of several malignancies. The wee1 kinase is responsible 
for adding inhibitory phosphorylation to the tyrosine-15 residue of 
CDK1[146,214].  This phosphorylation is required for the activation of S-phase 
and G2/M cell cycle checkpoints through the CHK1 pathway which inhibits cdc25 
phosphatases, which under normal circumstances constitutively remove the 
inhibitory phosphates, keeping CDKs active[115,149,179,232].  Therefore, 
preventing this initial phosphorylation event should abrogate these checkpoints 
that are induced by genotoxic chemotherapy drugs. Indeed, early studies have 
demonstrated a benefit of combining the first-in-class wee1 inhibitor, MK-1775 
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(currently in Phase 1 and 2 clinical trials), with standard chemotherapy drugs in a 
variety of malignancies, including AML[15,23,60,69,70,99,160,208].  
 In this study, we investigated the potential role for the addition of MK-1775 
to araC for the treatment of DS-AML. Using the clinically relevant DS AMKL cell 
lines, CMK and CMY, and ex vivo primary DS-AML blast samples, we 
determined that MK-1775 was able to synergistically enhance the cytotoxicity of 
araC.  Furthermore, using the cell line models, we determined that MK-1775 
enhanced araC-induced apoptosis, likely by enhancing S-phase DNA damage 
caused by araC.  These results support the further development of the wee1 
inhibitor MK-1775 for the treatment of DS-AML. 
4.2 Methods 
4.2.1 Cell Lines, Culture Conditions, and Reagents 
CMK cells were purchased from the German Collection of Microorganisms and 
Cell Cultures (DSMZ; Braunschweig, Germany).  The CMY cell line was a gift 
from Dr. A. Fuse, (National Institute of Infectious Diseases, Tokyo, Japan).  The 
DS-AMKL cell lines CMK and CMY were both cultured in RPMI 1640 with 10% 
FBS (Life Technologies, Carlsbad, CA, USA) and 2 mM L-glutamine plus 100 
U/ml penicillin and 100 µg/ml streptomycin (Life Technologies), in a 37°C 
humidified atmosphere containing 5% CO2/95% air.  AraC was purchased from 
Sigma (St. Louis, MO, USA) and MK-1775 was purchased from Selleck Chemical 
(Houston, TX, USA).  Diagnostic blast cells from DS children with AMKL (n=2) 
were obtained from the Children’s Hospital of Michigan leukemia cell bank.  Both 
patients remain in first remission.  Written consent was obtained according to the 
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Declaration of Helsinki. The research protocol was approved by the Human 
Investigation Committee of Wayne State University School of Medicine. 
4.2.2 Antibodies 
Rabbit antibodies directed against wee1, p-CDK1 (Y15), total CDK1, PARP, 
phosphorylated histone H3(S10) (pH3) and γH2AX were purchased from Cell 
Signaling Technologies (Danvers, MA, USA).  Mouse anti-β-actin was purchased 
from Sigma.  Goat anti-rabbit IRDye 800CW antibody for western blots was 
purchased from Licor (Lincoln, NE, USA). Goat anti-rabbit-Alexa-488 for flow 
cytometry was purchased from Life Technologies.   
4.2.3 In Vitro Cytotoxicity Assay 
Viable cells were determined using a standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assay as previously described[49].  
Briefly, cells were added to a 96-well plate and cultured in the presence of 
increasing drug concentrations for 72 hours.  After 72 hours, MTT (Sigma, St. 
Louis, MO, USA) was added to a final concentration of 1mM.  After four hours, 
formazan crystals were solubilized by addition of 10 mM HCl/10% sodium 
dodecyl sulfate (SDS).  Crystals were allowed to dissolve overnight and plates 
were read using a microplate reader at 590 nm.  For patient samples, 50,000 
cells per well were cultured for 48 hours with ITS (Sigma) and conditioned media 
(20% supernatant from 5637 bladder cancer cell line – a source of GM-CSF) in 
the presence of various drug concentrations, after which MTT addition occurred 
as above.  The presence or absence of synergistic drug interactions was 
determined using the Compusyn software (Combosyn, Parasmus, NJ, USA)[27].  
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Error bars represent standard error on the mean, determined from at least three 
independent experiments.  When indicated, IC50s were compared using non-
parametric Mann-Whitney U test using GraphPad Prism 5 software (GraphPad 
Software, La Jolla, CA, USA) 
4.2.4 Lentiviral shRNA Knockdown of wee1 Expression 
Lentivirus mediated gene expression knockdown was performed, as described 
previously[224].  Lentivirus shRNA constructs directed against WEE1 
(designated sh-Wee1) or against no known gene (designated sh-NTC) were 
purchased from Sigma.  Mixed cultures expressing the shRNA of interest were 
selected for by adding puromycin (Invivogen, San Diego, CA, USA) to the 
standard culture media.  Knockdown was confirmed by both quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) and western blot. 
4.2.5 Western Blotting 
Western blots were performed as previously described[35].  Briefly, cell lysates 
were prepared in the presence of protease and phosphatase inhibitors (cOmplete 
Mini and PhosStop, Roche, Indianapolis, IN, USA).  Cell lysates were subjected 
to SDS-PAGE and transferred to PVDF membranes (Pierce Scientific, Rockford, 
IL, USA) for blotting with antibodies.  Membranes were scanned using an 
Odyssey scanner (Licor).  Images are representative of at least 3 identical, 
independent experiments. 
4.2.6 qRT-PCR 
qRT-PCR was performed as previously described[35].  Briefly, TaqMan probes 
from Life Technologies (Carlsbad, CA, USA) directed against either WEE1 or 
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GAPDH mRNA were used for amplification and detection.  Relative transcript 
levels were determined using the delta-delta-CT method[117] and the experiment 
was performed on a LightCycler 480 instrument (Roche, Indianapolis, IN, USA) 
4.2.7 Flow Cytometry 
Flow cytometry for apoptosis was performed using AnnexinV/Propidium iodide 
(PI) dual staining, as described previously[225]. Analysis of γH2AX and pH3 vs 
PI was performed using a protocol from Huang and Darzynkiewicz[82], with the 
following modifications.  One million cells per condition were spun at 300 rcf for 4 
minutes and resuspended in 0.5 mL of 1% formaldehyde at 4°C for 15 minutes.  
Samples were spun and resuspended in residual volume, followed by dropwise 
addition of 1mL of ice-cold methanol and storage at 4°C for at least 30 minutes.  
Samples were then processed according to protocol, using the antibody dilutions 
recommended by the manufacturer with overnight primary incubation.  Samples 
were then counterstained with PI and analyzed as above.  Histograms were 
analyzed with FlowJo (TreeStar Software, Ashland, OR, USA).  Images are 
representative of at least 2 identical, independent experiments.  Where indicated, 
statistical analyses were performed using a paired t-Test. 
4.3 Results 
4.3.1 MK-1775 Has Single Agent Effect in DS-AML 
 To investigate the potential of targeting wee1 for the treatment of DS-AML, 
two clinically relevant cell lines were used: CMK and CMY (which were derived 
from a patient who initially responded to chemotherapy and a patient who had 
refractory disease, respectively)[131,181].  Each cell line was originally derived 
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from a pediatric DS patient with AMKL and a confirmed GATA1 mutation.  As can 
be seen in Figure 4.1A, CMK is much more sensitive (>50-fold) to araC than is 
CMY.  CMY was also significantly more resistant to ara-C-induced apoptosis as 
measured by AnnexinV/PI staining by flow cytometry compared to the CMK line 
(Figure 3D&E). CMY demonstrated (using clinically achievable drug 
concentrations) class-wide resistance to both nucleoside analogues and 
topoisomerase poisons (Table 4.1).  Interestingly, the cross resistance 
demonstrated by CMY was not seen with MK-1775 (Figure 4.1B) with CMK and 
CMY having IC50s of 291 and 316 nM, respectively (p=1.0).  MK-1775 was able 
to induce comparable, dose-dependent levels of apoptosis in both cell lines 
(Figure 4.1C).  Knockdown of wee1 expression using lentiviral delivery of shRNA 
(Figure 4.1D&E) was able to further sensitize both cell lines to MK-1775, 
suggesting that the effects of this drug are on-target. 
4.3.2 Pharmacodynamic Changes of CDK1 Phosphorylation after Treatment 
with MK-1775 
 Additional studies examined what dose schedule of MK-1775 would be the 
most effective for combination treatments.  CMK and CMY cells were treated with 
increasing concentrations of MK-1775 for 24 hours, and phosphorylation status 
of CDK1(Y15) was interrogated using western blots (Figure 4.2A&B).  After 24 
hour treatment, it was found that concentrations as low as 100 nM were able to 
cause near-maximal inhibition of CDK1 phosphorylation.  To determine the 
temporal kinetics of this inhibition, cells were treated with 100 nM MK-1775, 
followed by drug washout (Figure 4.2A&B). Four hours of treatment was 
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sufficient to decrease CDK1 (Y15) phosphorylation, but the effect was transient, 
returning as soon as 1 hour post-drug washout.  Based on these findings, it was 
determined that simultaneous treatment would be utilized for further experiments. 
4.3.3 MK-1775 Enhances the Cytotoxic Effects of AraC 
 The combination of MK-1775 with araC resulted in a synergistic reduction 
in viable cells (Figure 4.3A&B), with CI values ranging from 0.57-0.74 and 0.7-
0.77 for CMK and CMY, respectively (CI values <1 indicate synergism, =1 
indicate additivity, and >1 indicate antagonism).  Knockdown of wee1 was able to 
enhance araC-induced cytotoxicity in both cell lines (Figure 4.3C).  To investigate 
whether MK-1775 could enhance araC-induced apoptosis, flow cytometry 
analysis of AnnexinV/PI dual-staining was used.  MK-1775 (100 nM) was able to 
greatly enhance the apoptosis induced by araC in both cell lines (Figures 
4.3D&E). Treatment of two diagnostic DS AMKL samples with varying doses of 
araC and MK-1775 yielded synergistic inhibition of viable cells, with CIs ranging 
from 0.28 to 0.65 (Figure 4.3F), confirming that these drug combinations could 
ultimately be incorporated into clinical protocols.  
4.3.4 MK-1775 Enhances AraC-induced DNA Damage in S-Phase 
 To begin elucidating the mechanism by which the combination of MK-1775 
and araC-induced apoptosis, CMK and CMY cells were treated for 24 hours with 
combinations of both agents and levels of pCDK1(Y15), PARP cleavage, and 
γH2AX (a biomarker for DNA double strand breaks) were interrogated using 
western blots. It is well-known that araC can cause replication stress, which 
results in DNA damage and cell-cycle arrest through the ATR-CHK1 
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pathway[177]. Therefore, it was important to determine whether MK-1775 could 
abrogate the inhibition of CDK1 that results from activation of this checkpoint, 
preventing cell cycle arrest.  We hypothesized that MK-1775 would be able to 
enhance araC-induced DNA damage as inhibition of wee1 alone can cause 
replication stress, as well as inhibition of DNA repair.  Indeed, MK-1775 was able 
to abrogate the induction of pCDK1(Y15) and increase γH2AX induction by araC 
in a dose-dependent fashion that paralleled the induction of apoptosis (measured 
by PARP cleavage) (Figure 4.4). 
 There have been several reported mechanisms by which MK-1775 can 
enhance the cytotoxicity of different chemotherapeutic agents including wee1 
inhibition, which prevents activation of the G2/M DNA damage checkpoint, 
allowing cells to progress aberrantly through the cell cycle and resulting in either 
apoptosis or mitotic catastrophe. MK-1775 can also induce unscheduled mitosis, 
which typically results in cell death.  To assess for these mechanisms, cells were 
treated with araC, MK-1775, or the combination for 24 hours and p-H3 (a marker 
for mitosis) and γH2AX status were interrogated using flow cytometry.  AraC 
alone induced S-phase arrest, while MK-1775 alone had little impact on the cell 
cycle profiles of CMY and CMK cells (Figures 4.5 and 4.6, respectively).  While 
the combination appeared to result in a slight rightward shift of the early-S peak 
seen from araC alone, possibly indicating abrogation of an early-S arrest by MK-
1775, the most notable change seen in the combination treatment was the 
significant increase in apoptosis as measured by cells with sub-G1 DNA content. 
Additionally, it does appear that MK-1775 was able to decrease the amount of 
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G2/M and S-phase after araC treatment in CMY and CMK, respectively (Figures 
4.5-4.8). Though MK-1775 alone may have had a small impact on the number of 
mitotic cells, (Figures 4.5 and 4.6), it did not appear to have caused the degree of 
unscheduled mitoses reported previously in other cell types, and the modest 
nature of these changes is unlikely to account for the amount of cell death seen.  
Interestingly, MK-1775 was able to enhance araC-induced γH2AX primarily in S-
phase in CMY cells (Figure 4.5).  In CMK cells, the addition of MK-1775 to even 
low concentrations of araC was able to primarily target cells in S-phase (Figure 
4.6, 4.8), however it is unclear whether the increase in DNA damage shown in 
Figure 4.4 occurred prior to or after the onset of apoptosis.  It was expected that 
if MK-1775 primarily enhanced araC-induced cell death by abrogation of G2/M 
checkpoint, there would have been an increase in γH2AX+ cells in the G2/M 
compartment.  The dearth of G2/M cells that stained positively for γH2AX 
therefore is suggestive that the addition of MK-1775 to araC was able to cause 
sufficient insult to cells that they simply underwent apoptosis directly from S-
phase.  
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Table 4.1  IC50s for nucleoside analogues and topoisomerase II poisons 
 
 
Figure 4.1  MK-1775 has single agent effect against DS-AML.  A: AraC IC50s for CMK and 
CMY after 72 hour treatment as determined by MTT.  CMY is approximately 60-fold more 
resistant to araC than CMK.  B:  CMK and CMY cells are comparably sensitive to MK-1775 as 
determined by a 72-hour MTT assay.  C:  MK-1775 is able to induce comparable, albeit modest 
dose-dependent apoptosis in both cell lines after 48-hour treatment, as determined by 
AnnexinV/PI staining.  D-E:  Stable knockdown of wee1 using a lentivirus delivery system and 
selection by puromycin resulted in reductions in wee1 levels as well as p-CDK(Y15) levels.  F:  
Knockdown of wee1 sensitized CMK and CMY cells to MK-1775, as determined by a 72-hour 
MTT assay. 
  
Drug CMK CMY Fold 
Clofarabine 14 350 25.0*
Decitabine 50 1099 21.8*
Daunorubicin 88 209 2.4*
Etoposide 1251 4432 3.5*
Mitoxantrone 12 69 5.8*
* indicates p<0.05
IC50 (nM)
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Figure 4.2  Pharmacodynamic changes in p-CDK1(Y15) after MK-1775 treatment.  Top: 
CMK and CMY (A&B) cells were treated for 24 hours with increasing concentrations of MK-1775 
and probed for CDK1(Y15) phosphorylation by western blot.  Treatment for 24-hours with 100 nM 
MK-1775 was able to cause near-maximal reduction of CDK1(Y15) phosphorylation in both CMK 
and CMY.  Bottom: CMK and CMY (A&B) cells were treated with 100 nM MK-1775 for 4 hours 
followed by drug washout.  Treatment with MK-1775 was able to inhibit CDK1 phosphorylation 
after only four hours, but this phosphorylation returned after only 1 hour. 
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Figure 4.3  MK-1775 synergizes with araC in both cell lines and primary patient samples.  
A-B:  CMK and CMY cells were treated with different combinations of araC and MK-1775 for 72-
hour and viability was determined by MTT assay.  Standard, normalized isobolograms 
demonstrate the synergistic inhibition of cell viability by the combination of araC and MK-1775.  
C: CMK and CMY –ntc and –shwee1 cells were treated for 72 hours with araC and viability was 
determined by MTT.  Knockdown of wee1 sensitized both cell lines to araC.  D-E:  CMK (D) and 
CMY (E), were treated with varying doses of araC in the presence or absence of 100 nM MK-
1775 for 48 hours and apoptosis was measured using AnnexinV/PI staining.  F:  Various 
combinations of araC and MK-1775 were tested in 2 primary DS-AML samples ex vivo using 48-
hour MTT.  The CI-Fa plot shows the combination index vs. the fraction affected, with CI < 1 
representing synergy. 
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Figure 4.4  MK-1775 can abrogate araC-induced CDK1(Y15) phosphorylation and enhance 
araC-induced DNA damage.  CMK and CMY cells were treated for 24 hours with the indicated 
drugs.  MK-1775 was able to, in a dose dependent fashion, decrease CDK1(Y15) 
phosphorylation and increase araC-induced DNA damage (γH2AX) and apoptosis (PARP 
cleavage). 
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Figure 4.5  MK-1775 effects on cell cycle, mitosis, and DNA damage.  CMY cells were treated 
with the indicated drug for 24 hours and analyzed by flow cytometry.  Top: The effects of araC 
and MK-1775 on cell cycle were determined using PI staining.  Middle:  The effects of araC and 
MK-1775 on mitosis vs. cell cycle were determined using dual pH3/PI staining.  Bottom:  The 
effects of araC and MK-1775 on DNA damage vs cell cycle were determined using dual 
γH2AX/PI staining. * indicates p<0.05 compared to araC treatment. 
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Figure 4.6  MK-1775 effects on cell cycle, mitosis, and DNA damage.  CMK cells were treated 
with the indicated drug for 24 hours and analyzed by flow cytometry.  Top: The effects of araC 
and MK-1775 on cell cycle were determined using PI staining.  * indicates p<0.05 compared to 
araC treatment.  Middle:  The effects of araC and MK-1775 on mitosis vs. cell cycle were 
determined using dual pH3/PI staining.  Bottom:  The effects of araC and MK-1775 on DNA 
damage vs cell cycle were determined using dual γH2AX/PI staining. 
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Figure 4.7  MK-1775 can decrease G2/M fraction of viable CMY cells, especially at higher 
doses.  CMY cells were treated with the indicated drug for 24 hours and analyzed by flow 
cytometry using PI staining.  Non-viable (sub-G1) cells were gated out to facilitate analysis of 
viable cell cycle profile, as higher MK-1775 doses (300 and 400 nM) in the combination treatment 
resulted sub-G1 populations  >50%, obfuscating cell-cycle changes.  * indicates p<0.05 
compared to araC treatment.   
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Figure 4.8  CMK cells treated with the combination of araC and lower doses of MK-1775 
appear to die out of S-phase.  CMK cells were treated with the indicated drug for 24 hours and 
analyzed by flow cytometry using dual γH2AX/PI staining.  The left panel for each treatment 
shows the two-dimensional histogram while the right panel shows the cell cycle analysis using 
only PI staining. 
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Figure 4.9  Schematic of MK-1775 and araC effects on cell survival.  A:  In the absence of 
either drug, wee1 inhibits CDK1 by phosphorylation at Y15.  Cdc25 phosphatases constitutively 
remove this phosphorylation, with the net result being cell growth and survival.  B:  When araC is 
present, it can incorporate into newly synthesized DNA, causing chain termination and 
subsequent DNA damage and checkpoint activation.  This inactivates cdc25 phosphatases, with 
the result being cell cycle arrest.  In some cells, this leads to cell death, however most cells are 
able to repair the damage and survive.  C:  In the presence of MK-1775, wee1 cannot inhibit 
CDK1, so it remains active and DNA replication occurs unimpeded.  Unregulated replication 
results in some DNA damage and cell death due to lack of necessary cofactors and inability to 
activate cell cycle checkpoints, but the net result is largely cell survival.  D:  In the presence of 
both drugs, replication continues despite DNA damage induced by araC.  The inhibition of wee1 
by MK-1775 makes cell cycle checkpoint activation irrelevant.  AraC continues to incorporate into 
newly firing replication forks, resulting in large amounts of DNA damage.  The result is then 
primarily cell death by apoptosis. 
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4.4 Discussion 
 DS children with AML have an overall very favorable prognosis with event-
free survival rates of ~80%[223].  However, for patients with either refractory or 
relapsed disease, the prognosis is very poor highlighting the need to develop 
new effective therapeutic options.  Targeting the wee1 kinase for treatment of 
malignancy is rapidly emerging with several phase 1 or phase 2 clinical trials 
currently underway (www.clinicaltrials.gov), including one pediatric brain tumor 
trial. In our study, we provide strong evidence to support the further development 
of combining the wee1 inhibitor MK-1775 with araC for the treatment of DS-AML.   
 Early published results from phase 1 trials have indicated that the maximal 
plasma concentration of MK-1775 is approximately 400-500 nM, with an oral 
twice daily dosing regimen for 5 doses [108,206].  Though single-agent activity of 
MK-1775 at those levels appears to be modest, the concentrations used in this 
study (100-200 nM) for combination studies are well below that threshold.  
Therefore, even if substantial dose reductions are necessary in this population, 
our findings are likely to have clinical relevance.  Furthermore, based on the 
results from Figure 4.2 suggesting that araC and MK-1775 should likely be dosed 
simultaneously, the MK-1775 dosing strategy used previously is likely compatible 
with the 4-day infusion schedule for araC used in the most recent DS-AML 
clinical trial, Children’s Oncology Group AAML0431.  Although this study lacks in 
vivo toxicity and efficacy data, a recently published study using a murine AML 
model found that the toxicity of the combination was similar to that of araC 
alone[208].   
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 Most of the prior studies investigating MK-1775 focused on its ability to 
abrogate a G2/M cell cycle checkpoint to enhance cell death.  It was initially 
reported that this response was only effective in p53-mutant cells, though that 
notion has been challenged and may represent a cancer- or cell-type-specific 
phenomenon[1,15,23,60,69,70,99,160,208].  While similar results were expected 
in our study, it was surprising to see that G2/M checkpoint abrogation did not 
seem to contribute substantially to the cytotoxic effect of the combination of MK-
1775 and araC, and instead cells were likely dying in S-phase (Figures 4.5-4.8).  
Although it would be ideal if MK-1775 synergizes with anthracycline 
chemotherapy, the lack of substantial G2/M arrest abrogation, and unfavorable 
previously published results[208] suggest that this is likely not the case.   It is 
important to note that these findings do not contradict those seen in previous 
studies (G2/M abrogation, unscheduled mitosis), given that those studies were 
performed using mostly solid tumor lines.  Instead, our results agree with a 
recently published study that suggests MK-1775 is able to abrogate an intra-S 
checkpoint[208].  With this in mind, we propose a model (illustrated in Figure 4.9) 
in which wee1 inhibition by MK-1775 prevents activation of the S-phase 
checkpoint normally activated by araC.  Subsequently, replication forks continue 
to fire [8,9], allowing for more araC incorporation and subsequent fork collapse.  
Eventually, a catastrophic level of DNA damage is sustained, and the cell 
undergoes apoptosis without completing DNA replication.  Though further work is 
necessary to fully confirm this hypothesis, if true, it could have important 
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implications for the combination of MK-1775 with nucleoside analogues that rely 
on DNA synthesis for anti-tumor effect.   
 As a whole, the data presented here support the further development of 
MK-1775 as a potential adjuvant to araC for the treatment of DS-AML.  MK-1775 
is able to greatly enhance the anti-leukemic effects of araC, primarily by 
enhancing araC’s DNA damaging effect in S-phase. The anti-leukemic effect was 
independent of sensitivity to araC alone, and was validated ex vivo using primary 
DS-AML blasts. Based on our results, MK-1775 appears to be an exciting new 
option for the treatment of relapsed or refractory DS-AML and for further clinical 
trial development which may also be relevant to non-DS AML patients as well. 
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CHAPTER 5 – Discussion and Future Directions 
 Despite great advances in the treatment of AML, it remains deadly for 
many of the children affected by this disease.  Fortunately, by utilizing carefully 
designed clinical trials and conducting relevant bench research, advances in the 
treatment of these patients will continue to be made.  
 Previous studies on the biology of DS-AML blasts found that, at least 
partially as a result of modulated GATA1 function, these blasts were more 
sensitive to chemotherapy [51,53,201-203].  The finding that lower GATA1 
activity in DS-AML blasts positively impacts outcome for those patients led to the 
hypothesis that higher GATA1 activity in non-DS AMKL cases may have the 
opposite effect.  Indeed, as the results in Chapter 2 of this work show, this turned 
out to be the case.  GATA1 was overexpressed in AML cases of the AMKL 
phenotype compared to non-AMKL cases, and knockdown of GATA1 in a 
megakaryocytic AML cell line was found to enhance sensitivity to both araC and 
DNR.  One mechanism by which GATA1 conveys chemotherapy resistance is 
that GATA1 affects the expression of the anti-apoptotic Bcl-2 family protein Bcl-
xL.  Furthermore, it was shown that treatment with the HDAC inhibitor VPA was 
able to down-regulate both GATA1 and Bcl-xL sensitizing cells to treatment with 
araC. 
In addition to the additional GATA1 target genes identified for future study, 
the results in Chapter 2 have potential therapeutic implications.  In the non-DS 
AML population, the AMKL subtype is considered to be high risk with a relatively 
poor prognosis (EFS < 35%) [5,140,173]; therefore novel therapies that may be 
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especially useful in this patient group are of interest.  Since the completion of the 
work presented in Chapter 2, novel HDAC inhibitors have been developed 
clinically, such as panobinostat and vorinostat (reviewed in[134,155]).  With new 
agents, it may be possible to target mechanisms of resistance including 
overexpression of GATA1, even though such targets had previously been 
considered “undruggable.”  Additionally, the confirmation of Bcl-xL as contributing 
to the resistance in AMKL offers another potential avenue for therapeutic 
intervention.  There has been great interest in targeting the anti-apoptotic Bcl-2 
family proteins in recent years, as inhibition of these proteins has been shown to 
be effective in a variety of malignancies[33,139].  It does merit note, however, 
that this excitement is somewhat tempered by the finding that inhibition of Bcl-xL 
may lead to thrombocytopenia[168,221], highlighting the benefit vs. risk balance 
which must be considered when developing new cancer therapies. 
With regard to DS-AML, the important findings presented in this work 
include the identification of wee1 inhibition by MK-1775 as an attractive option for 
further pre-clinical and clinical development.  Despite the otherwise promising 
compounds in Chapter 3 not being as effective as hoped, the results from the 
MK-1775 are encouraging.  As a single agent, MK-1775 demonstrated 
comparable effects in both the CMK and CMY cell lines, albeit at concentrations 
toward the high end of what is clinically achievable.  However, in combination 
with araC, MK-1775 was able to enhance the inhibitory effect of araC in a 
synergistic fashion.  Importantly, from the results presented in Chapter 4, it 
appears that MK-1775 exerts its effects on CMK and CMY cells primarily in S-
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phase, a finding that was largely unexpected, as previous studies had largely 
suggested that inhibiting wee1 targets cells in G2 [1,15,23,60,69,70,99,160,208]. 
The role of wee1 in human cells is to maintain inhibitory phosphorylation 
on CDK1 and CDK2 such that CDK activity is controlled appropriately according 
to the phase of the cell cycle.  Though initial studies of MK-1775 were focused on 
a G2-phase effect, the results presented here, especially in combination with 
work from other groups, suggest that there is an important role for MK-1775 in 
the targeting of S-phase cell cycle control [153,208]. Moving forward, it will be 
important to further clarify the mechanism by which MK-1775 exerts these effects 
so that its maximal therapeutic potential may be realized. 
 From previous studies, it is clear that there is a role for CDK1 in the 
control of S-phase regulation.  It has been shown that forced activation of CDK1 
by inhibition or knockdown of wee1 causes S-phase DNA damage, as well as 
increased replication fork firing and decreased fork length[8,9].  Furthermore, it 
was shown that the shorter fork lengths were thought to be caused by an 
insufficient supply of necessary cofactors, a phenotype which was partly 
reversed by adding exogenous nucleosides[8].  This potentially offers 
mechanistic insight into the recent findings that MK-1775 was able to enhance 
sensitivity to pemetrexed, an antifolate that reduces available nucleoside 
pools[208].  If the effect of MK-1775 treatment really is predominantly in the S-
phase, it would be expected that it would synergize better with agents that act in 
S-phase (and activate S-phase DNA damage checkpoints) than agents that act 
in G2 (activating G2/M DNA damage checkpoints).  This is indeed the case, at 
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least for CMK and CMY cells (Figure 5.1).  It was found that for both cell lines, 
the combination with MK-1775 demonstrated greater synergy with the nucleoside 
analogues araC, decitabine, and clofarabine, than it did with the Topo2 poisons 
DNR, VP16, and the mitotic inhibitor vincristine (VCR).   
Another question regarding the activity of MK-1775 is whether or not it 
primarily exerts its effect on CDK1 or CDK2.  Traditionally, CDK1 has been 
considered to be the CDK responsible for driving mitosis, while CDK2 drives 
DNA replication.  This notion was challenged, however, when it was 
demonstrated that not only can CDK1 perform the roles of CDK2[4], but CDK1 is 
capable of compensating for CDKs 2,3,4, and 6.  In fact, those kinases are all 
dispensable, but the roles of CDK1 cannot be performed by its family members 
and CDK1 knockout produces non-viable embryos[180].  Importantly, wee1 is 
capable of regulating CDK2 as well as CDK1, as the two proteins share 
homologous N-termini, which include the regulatory tyrosine 15[28,59].  In fact, a 
constitutively active CDK2 knock-in mutant reproduced many of the phenotypes 
seen in wee1 depleted cells[85].  Furthermore, pan-CDK inhibition with 
Roscovitine was able to antagonize the MK-1775 effect more than was specific 
CDK1 inhibition with RO-3306 in CMK and CMY cells (Figure 5.2).  It will be 
important to use more specific approaches to further assess these differences in 
the future. 
Though these differences in potential mechanisms of action may seem 
insignificant at first, given the similar phenotypes expected, determining the 
major mechanisms at play is still important.  First, better understanding the 
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mechanism by which wee1 inhibition enhances araC-induced apoptosis of AML 
cells allows for better treatment design.  It also allows for the potential 
identification of new drug targets that are in the affected pathway, which might 
have fewer side effects.  Finally, and perhaps most importantly in the short-term, 
if treatment with MK-1775 predominantly affects S-phase arrest, agents that 
target S-phase cells should be preferentially combined with MK-1775 in clinical 
trials. 
In conclusion, the work presented in this dissertation describes preclinical 
efforts at improving outcomes for pediatric AML patients in both the DS and the 
non-DS populations.  The findings presented in Chapter 2 demonstrate a 
potential for using novel therapies, like HDAC or Bcl-2 family inhibitors to treat 
AMKL, as well as offering insight into the mechanisms of resistance in a difficult 
to treat disease.  Those findings presented in Chapters 3 and 4 lay the 
foundation for the use of MK-1775 to enhance the effects of araC in DS-AML.  
Though there is always more to be elucidated, the studies described herein set 
the stage for such further work, with the eventual goal of improving outcomes for 
pediatric AML.  
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Figure 5.1  Isobolograms and CIs for the combination of MK-1775 with various cell-cycle-
specific agents.  Construction of isobolograms and CI plots as performed as in Chapter 3.  CMK 
and CMY cells were treated for three days in the presence of increasing concentrations of the 
indicated drug with or without increasing concentrations of MK-1775 for 72 hours and analyzed 
using standard MTT assay.  TOP:  MK-1775 was combined with either DNR, VP16, or VCR (left-
top) and either decitabine, clofarabine, or araC (right-top).    BOTTOM:  The CIs from the top 
panel were segregated by cell line and by whether the non-MK-1775 agent targets S- or G2/M-
phase cells.  Within each cell line, G2/M and S groups were found to be significantly different 
using the non-parametric Kruskal-Wallis test with Dunn’s post-test correction (*).  When the cell 
lines are combined, the G2/M values are significantly different than S values (p<0.0001) using the 
non-parametric Mann-Whitney U test (†). 
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Figure 5.2  Isobolograms and CIs for the combination of MK-1775 and either Roscovitine 
or RO-3306 in CMK and CMY cells.  Construction of isobolograms and CI plots was performed 
as in Chapter 3.  CMK and CMY cells were treated for three days in the presence of increasing 
concentrations of MK-1775 with or without increasing concentrations of either Roscovitine or RO-
3306 and for 72 hours and analyzed using standard MTT assay.  Note that the scale for the 
roscovitine isobolograms and CI plot is much larger than in previous figures. 
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 Acute myeloid leukemia (AML) is a potentially devastating disease that 
can affect people of all ages.  While there are certain patient groups that typically 
have favorable outcomes, in the pediatric population, overall survival (OS) is 
approximately 70%, leaving much progress to be made.  Children with Down 
syndrome (DS) have a substantially elevated risk for developing AML, especially 
of the megakaryocytic phenotype (AMKL).   
 Patients with DS AMKL almost universally harbor a mutation in the gene 
encoding the GATA1 transcription factor, resulting in the translation of a short-
form protein GATA1s, which has been shown to contribute to chemotherapy 
sensitivity.  In contrast, in non-DS patients, overexpression of GATA1 has been 
correlated with poorer outcomes.  In the first half of this work, we investigated the 
role that elevated GATA1 expression plays on the sensitivity of AMKL cells to 
chemotherapy.  To begin, we confirmed that amongst non-DS patients, GATA1 
transcripts were significantly higher in AMKL blasts compared to blasts from 
other AML subgroups. Further, GATA1 transcript levels significantly correlated 
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with transcript levels for the anti-apoptotic protein Bcl-xL in our patient cohort.  
We demonstrated that Bcl-xL is a GATA1 target, and knockdown of GATA1 with 
shRNA sensitizes cells to chemotherapy treatment and decreases Bcl-xL 
expression.  Treatment of Meg-01 cells with the histone deacetylase inhibitor 
valproic acid resulted in down-regulation of both GATA1 and Bcl-xL and 
significantly enhanced ara-C sensitivity. Furthermore, additional GATA1 target 
genes were identified by oligonucleotide microarray and ChIP-on-Chip analyses.  
 While OS for DS AML is generally very favorable (approximately 90%), DS 
patients with refractory or relapsed disease have dismal prognoses, with OS in 
that group only approximately 25%.  Therefore, there is a need for the 
development of new therapeutic approaches for these patients.  In the second 
half of this work, we investigated the response of 2 DS AML cell lines, CMK and 
CMY, to the combination of araC and one of either the aurora A kinase inhibitor 
MLN8237, the aurora B kinase inhibitor AZD1152-HQPA, the Plk1 inhibitor 
BI6237, or the wee1 inhibitor MK-1775.  It was found that MK-1775, in contrast to 
the other three agents, synergized with araC in antiproliferative MTT assays in 
both cell lines as well as in ex vivo DS-AML primary patient samples.  MK-1775 
was able to decrease inhibitory CDK1(Y15) phosphorylation after only 4 hours, 
and was able to enhance araC-induced DNA damage in S-phase and partially 
abrogate araC-induced cell cycle arrest. 
The work presented in this dissertation describes preclinical efforts at 
improving outcomes for pediatric AML patients in both the DS and the non-DS 
populations.  The findings presented demonstrate a potential for using novel 
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therapies, including HDAC or Bcl-2 family inhibitors to treat AMKL, as well as 
offering insight into the mechanisms of resistance in a difficult to treat disease.  
Furthermore, these findings lay the foundation for the use of MK-1775 to 
enhance the effects of araC in DS-AML.  Though there is always more to be 
elucidated, the studies described herein set the stage for such further work, with 
the eventual goal of improving outcomes for pediatric AML.  
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